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A B S T R A C T
Background
Oral mucositis is a side eEect of chemotherapy, head and neck radiotherapy, and targeted therapy, aEecting over 75% of high risk
patients. Ulceration can lead to severe pain and diEiculty eating and drinking, which may necessitate opioid analgesics, hospitalisation and
nasogastric or intravenous nutrition. These complications may lead to interruptions or alterations to cancer therapy, which may reduce
survival. There is also a risk of death from sepsis if pathogens enter the ulcers of immunocompromised patients. Ulcerative oral mucositis
can be costly to healthcare systems, yet there are few preventive interventions proven to be beneficial. Oral cryotherapy is a low-cost,
simple intervention which is unlikely to cause side-eEects. It has shown promise in clinical trials and warrants an up-to-date Cochrane
review to assess and summarise the international evidence.
Objectives
To assess the eEects of oral cryotherapy for preventing oral mucositis in patients with cancer who are receiving treatment.
Search methods
We searched the following databases: the Cochrane Oral Health Group Trials Register (to 17 June 2015), the Cochrane Central Register of
Controlled Trials (CENTRAL) (Cochrane Library 2015, Issue 5), MEDLINE via Ovid (1946 to 17 June 2015), EMBASE via Ovid (1980 to 17 June
2015), CANCERLIT via PubMed (1950 to 17 June 2015) and CINAHL via EBSCO (1937 to 17 June 2015). We searched the US National Institutes
of Health Trials Registry, and the WHO Clinical Trials Registry Platform for ongoing trials. No restrictions were placed on the language or
date of publication when searching databases.
Selection criteria
We included parallel-design randomised controlled trials (RCTs) assessing the eEects of oral cryotherapy in patients with cancer receiving
treatment. We used outcomes from a published core outcome set registered on the COMET website.
Data collection and analysis
Two review authors independently screened the results of electronic searches, extracted data and assessed risk of bias. We contacted
study authors for information where feasible. For dichotomous outcomes, we reported risk ratios (RR) and 95% confidence intervals (CI).
For continuous outcomes, we reported mean diEerences (MD) and 95% CIs. We pooled similar studies in random-eEects meta-analyses.
We reported adverse eEects in a narrative format.
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Main results
We included 14 RCTs analysing 1280 participants. The vast majority of participants did not receive radiotherapy to the head and neck,
so this review primarily assesses prevention of chemotherapy-induced oral mucositis. All studies were at high risk of bias. The following
results are for the main comparison: oral cryotherapy versus control (standard care or no treatment).
Adults receiving fluorouracil-based (5FU) chemotherapy for solid cancers
Oral cryotherapy probably reduces oral mucositis of any severity (RR 0.61, 95% CI 0.52 to 0.72, 5 studies, 444 analysed, moderate quality
evidence). In a population where 728 per 1000 would develop oral mucositis, oral cryotherapy would reduce this to 444 (95% CI 379 to
524). The number needed to treat to benefit one additional person (NNTB), i.e. to prevent them from developing oral mucositis, is 4 people
(95% CI 3 to 5).
The results were similar for moderate to severe oral mucositis (RR 0.52, 95% CI 0.41 to 0.65, 5 studies, 444 analysed, moderate quality
evidence). NNTB 4 (95% CI 4 to 6).
Severe oral mucositis is probably reduced (RR 0.40, 95% CI 0.27 to 0.61, 5 studies, 444 analysed, moderate quality evidence). Where 300
per 1000 would develop severe oral mucositis, oral cryotherapy would reduce this to 120 (95% CI 81 to 183), NNTB 6 (95% CI 5 to 9).
Adults receiving high-dose melphalan-based chemotherapy before haematopoietic stem cell transplantation (HSCT)
Oral cryotherapy may reduce oral mucositis of any severity (RR 0.59, 95% CI 0.35 to 1.01, 5 studies, 270 analysed, low quality evidence).
Where 824 per 1000 would develop oral mucositis, oral cryotherapy would reduce this to 486 (95% CI reduced to 289 to increased to 833).
The NNTB is 3, although the uncertainty surrounding the eEect estimate means that the 95% CI ranges from 2 NNTB, to 111 NNTH (number
needed to treat in order to harm one additional person, i.e. for one additional person to develop oral mucositis).
The results were similar for moderate to severe oral mucositis (RR 0.43, 95% CI 0.17 to 1.09, 5 studies, 270 analysed, low quality evidence).
NNTB 3 (95% CI 2 NNTB to 17 NNTH).
Severe oral mucositis is probably reduced (RR 0.38, 95% CI 0.20 to 0.72, 5 studies, 270 analysed, moderate quality evidence). Where 427
per 1000 would develop severe oral mucositis, oral cryotherapy would reduce this to 162 (95% CI 85 to 308), NNTB 4 (95% CI 3 to 9).
Oral cryotherapy was shown to be safe, with very low rates of minor adverse eEects, such as headaches, chills, numbness/taste disturbance,
and tooth pain. This appears to contribute to the high rates of compliance seen in the included studies.
There was limited or no evidence on the secondary outcomes of this review, or on patients undergoing other chemotherapies, radiotherapy,
targeted therapy, or on comparisons of oral cryotherapy with other interventions or diEerent oral cryotherapy regimens. Therefore no
further robust conclusions can be made. There was also no evidence on the eEects of oral cryotherapy in children undergoing cancer
treatment.
Authors' conclusions
We are confident that oral cryotherapy leads to large reductions in oral mucositis of all severities in adults receiving 5FU for solid cancers.
We are less confident in the ability of oral cryotherapy to reduce oral mucositis in adults receiving high-dose melphalan before HSCT.
Evidence suggests that it does reduce oral mucositis in these adults, but we are less certain about the size of the reduction, which could
be large or small. However, we are confident that there is an appreciable reduction in severe oral mucositis in these adults.
This Cochrane review includes some very recent and currently unpublished data, and strengthens international guideline statements for
adults receiving the above cancer treatments.
P L A I N   L A N G U A G E   S U M M A R Y
Can keeping the mouth cold during cancer treatment help to prevent mouth soreness and ulcers in children and adults?
Review question
This review has been produced to assess whether or not keeping the mouth cold during cancer treatment, by using ice, ice-cold water, ice
cream or ice lollies/popsicles, can help prevent mouth soreness and ulcers in children and adults.
Background
People receiving treatment for cancer are at risk of developing a sore mouth and ulcers as a side eEect. This side eEect is called oral
mucositis and aEects over 75% of high-risk patients (those receiving radiotherapy to the head and neck or high-dose chemotherapy). The
pain caused by this condition can be severe and can stop the person's ability to eat and drink, which may mean they need to take strong
pain killers, stay in hospital and be fed through a tube into their stomach, or even into their veins. This in turn can lead to disruption to their
cancer treatment, meaning they are not receiving the best possible treatment. The results may be a reduction in the patient's chances of
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy (Review)
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survival, and increased costs to the healthcare system. Cancer patients have weakened immune systems due to their treatment, meaning
that their bodies are less able to fight infections. This can be a problem if bacteria enter the body through the ulcer, which is an open wound.
This can lead to sepsis (a dangerous inflammatory reaction of the body to infection), which requires antibiotics and hospitalisation, and
can cause death.
Oral cryotherapy is the cooling of the mouth using ice, ice-cold water, ice cream or ice lollies/popsicles. It is thought to help prevent oral
mucositis in people receiving certain types of chemotherapy because the coldness makes the blood vessels in the mouth more narrow,
and this reduces the amount of blood containing chemotherapy drugs from reaching the mouth and causing oral mucositis. It is a low-
cost, natural treatment without serious side eEects.
Study characteristics
Authors from the Cochrane Oral Health Group carried out this review of existing studies and the evidence is current up to 17 June 2015.
It includes 14 studies published from 1991 to 2015 in which 1316 participants were randomised (1280 of whom were included in the
analyses) to receive oral cryotherapy versus standard care (usually saline mouthrinses) or no treatment or a diEerent treatment or a
diEerent method of oral cryotherapy, and the number of people developing oral mucositis of diEerent severities was compared. Nearly all
the evidence was on adults receiving oral cryotherapy versus standard care or no treatment. This evidence fell into two main groups: 1)
adults receiving fluorouracil-based (5FU) treatment for solid cancers; or 2) adults receiving high-dose melphalan-based cancer treatment
before haematopoietic stem cell transplantation (HSCT). HSCT is given to help the body to produce all types of blood cells, which are
destroyed during cancer treatment.
Key results
There is evidence showing that oral cryotherapy can lead to large reductions in the numbers of adults who get oral mucositis of all
severities aNer receiving 5FU-based treatment for solid cancers. There is less certain evidence to suggest that oral cryotherapy may reduce
the numbers of adults who get oral mucositis aNer receiving high-dose melphalan-based cancer treatment prior to HSCT. The evidence
suggests that it does reduce oral mucositis in these adults, but the size of the reduction is much less certain. However, there is more certain
evidence that there is a large reduction in severe oral mucositis in these adults.
Oral cryotherapy did not cause any serious side eEects in any of the participants of these studies, and most people seemed able to carry
it out properly and complete it.
Quality of the evidence
The evidence presented, on the main outcome of whether or not people developed oral mucositis of all severities, is of moderate (because
the nature of the oral cryotherapy treatment meant that the studies could not be 'blinded' which is a desirable characteristic of these
studies) to low quality (because in addition to the above problem, the results of the individual studies were too diEerent to give a precise
result when they were combined).
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Summary of findings for the main comparison.   Cryotherapy versus control for preventing oral mucositis in adults receiving fluorouracil-based
treatment for solid cancers
Cryotherapy versus control for preventing oral mucositis in adults receiving fluorouracil-based treatment for solid cancers
Patient or population: adults** with solid cancers receiving fluorouracil-based cancer treatment
Setting: hospital
Intervention: cryotherapy
Comparison: control (no treatment or routine care)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
control
Risk with
cryotherapy
Relative ef-
fect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Oral mucositis (any) 728 per 1000 444 per 1000
(379 to 524)
RR 0.61
(0.52 to 0.72)
444
(5 RCTs)
⊕⊕⊕⊝
MODERATE 1
Oral cryotherapy reduced the risk of developing oral
mucositis by 39% (95% CI 28% to 48%). We would
need to treat 4 people (95% CI 3 to 5 people) with
oral cryotherapy to prevent 1 additional person from
developing oral mucositis
Oral mucositis (moder-
ate + severe)
530 per 1000 276 per 1000
(217 to 344)
RR 0.52
(0.41 to 0.65)
444
(5 RCTs)
⊕⊕⊕⊝
MODERATE 1
Oral cryotherapy reduced the risk of developing
moderate to severe oral mucositis by 48% (95% CI
35% to 59%). We would need to treat 4 people (95%
CI 4 to 6 people) with oral cryotherapy to prevent 1
additional person from developing moderate to se-
vere oral mucositis
Oral mucositis (severe) 300 per 1000 120 per 1000
(81 to 183)
RR 0.40
(0.27 to 0.61)
444
(5 RCTs)
⊕⊕⊕⊝
MODERATE 1
Oral cryotherapy reduced the risk of severe oral mu-
cositis by 60% (95% CI 39% to 73%). We would need
to treat 6 people (95% CI 5 to 9 people) with oral
cryotherapy to prevent 1 additional person from de-
veloping severe oral mucositis
Interruptions to cancer
treatment
400 per 1000 176 per 1000
(80 to 380)
RR 0.44
(0.20 to 0.95)
80
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2 3 4
Oral cryotherapy reduced the risk of treatment in-
terruption by 56% (95% CI 5% to 80%). We would
need to treat 5 people (95% CI 4 to 50 people) with
oral cryotherapy to prevent 1 additional person from
having a treatment interruption
C
o
ch
ra
n
e
L
ib
ra
ry
T
ru
ste
d
 e
v
id
e
n
ce
.
In
fo
rm
e
d
 d
e
cisio
n
s.
B
e
tte
r h
e
a
lth
.
  
C
o
ch
ra
n
e D
a
ta
b
a
se o
f S
ystem
a
tic R
e
vie
w
s
In
te
rv
e
n
tio
n
s fo
r p
re
v
e
n
tin
g
 o
ra
l m
u
co
sitis in
 p
a
tie
n
ts w
ith
 ca
n
ce
r re
ce
iv
in
g
 tre
a
tm
e
n
t: o
ra
l cry
o
th
e
ra
p
y
 (R
e
v
ie
w
)
C
o
p
yrig
h
t ©
 2016 T
h
e C
o
ch
ra
n
e C
o
lla
b
o
ra
tio
n
. P
u
b
lish
ed
 b
y Jo
h
n
 W
ile
y &
 S
o
n
s, Ltd
.
5
Oral pain (1 to 5 scale:
1 = never, 2 = 1 day of
week, 3 = 2 to 3 days of
week, 4 = most of week,
5 = 7 days of week)
The mean oral
pain (1 to 5
scale) was
3.64
The mean oral
pain (1 to 5 scale)
in the cryother-
apy group was
1.93 lower (2.37
to 1.49 lower)
- 80
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2 3 4
The duration of oral pain experienced was less in the
oral cryotherapy group (Additional Table 1)
Quality of life No studies assessed this outcome
Normalcy of diet (days
of total parenteral nutri-
tion)
No studies assessed this outcome
Duration of hospitalisa-
tion (days)
No studies assessed this outcome
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 All 5 studies at high risk of performance and detection bias
2 Single study at high risk of performance and detection bias
3 Low sample size and wide confidence interval
4 Indirect due to single study in 1 setting (in terms of country, healthcare system, and participants potentially diEering from other countries)
** There were no studies conducted on children
 
 
Summary of findings 2.   Cryotherapy versus control for preventing oral mucositis in adults receiving high-dose melphalan-based treatment prior to
haematopoietic stem cell transplantation for haematological cancers
Cryotherapy versus control for preventing oral mucositis in adults receiving high-dose melphalan-based treatment prior to haematopoietic stem cell transplanta-
tion for haematological cancers
Patient or population: adults** with haematological cancers receiving high-dose melphalan-based treatment prior to haematopoietic stem cell transplantation
Setting: hospital
Intervention: cryotherapy
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Comparison: control (no treatment or routine care)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
control
Risk with
cryotherapy
Relative ef-
fect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Oral mucositis
(any)
824 per 1000 486 per 1000
(289 to 833)
RR 0.59
(0.35 to 1.01)
270
(5 RCTs)
⊕⊕⊝⊝
LOW 1 2
Oral cryotherapy appears to reduce the risk of developing oral
mucositis. However, there is great uncertainty about our esti-
mate, and there is an extremely small chance of a 1% increase
in the risk of developing oral mucositis compared to control.
The point estimate suggests a 41% reduction in the risk of de-
veloping oral mucositis, with the confidence interval ranging
from a 65% reduction to a 1% increase in risk. We would need
to treat 3 people with oral cryotherapy to prevent 1 additional
person from developing oral mucositis, with the confidence in-
terval ranging from 2 people (to prevent 1 additional oral mu-
cositis case) to 111 people to cause 1 additional person to de-
velop oral mucositis
Oral mucositis
(moderate +
severe)
679 per 1000 292 per 1000
(115 to 741)
RR 0.43
(0.17 to 1.09)
270
(5 RCTs)
⊕⊕⊝⊝
LOW 1 2
Oral cryotherapy appears to reduce the risk of developing mod-
erate to severe oral mucositis. However, there is great uncer-
tainty about our estimate, and there is a very small chance of
a 9% increase in the risk of developing moderate to severe oral
mucositis compared to control. The point estimate suggests a
57% reduction in the risk of developing moderate to severe oral
mucositis, with the confidence interval ranging from an 83% re-
duction to a 9% increase in risk. We would need to treat 3 peo-
ple with oral cryotherapy to prevent 1 additional person from
developing moderate to severe oral mucositis, with the confi-
dence interval ranging from 2 people (to prevent 1 additional
moderate to severe oral mucositis case) to 17 people to cause 1
additional person to develop moderate to severe oral mucositis
Oral mucositis
(severe)
427 per 1000 162 per 1000
(85 to 308)
RR 0.38
(0.20 to 0.72)
270
(5 RCTs)
⊕⊕⊕⊝
MODERATE 1
Oral cryotherapy reduced the risk of developing severe oral
mucositis by 62% (95% CI 28% to 80%). We would need to treat
4 people (95% CI 3 to 9 people) with oral cryotherapy to pre-
vent 1 additional person from developing severe oral mucositis
Interruptions
to cancer
treatment
No studies assessed this outcome
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Oral pain on a
0 (no pain) to
10 (maximum
pain) scale
The weight-
ed mean oral
pain (0 to 10
scale) was
2.13
The mean oral
pain (0 to 10
scale) in the
cryotherapy
group was 1.5
lower (2.11 to
0.89 lower)
- 85
(2 RCTs)
⊕⊕⊝⊝
LOW 3 4
Oral cryotherapy reduced oral pain by 70% although the clin-
ical importance of a 1.5 point-reduction on a 0 to 10 scale is
questionable
Quality of life 1 study assessed this outcome but the data are currently unavailable as the study report and analysis have not yet been completed
Normalcy of
diet (days
of total par-
enteral nutri-
tion - TPN)
The mean
number of
days of TPN
was 7
The mean num-
ber of days of
TPN in the inter-
vention group
was 2.18 days
fewer (4.33 to
0.03 fewer)
- 78
(1 RCT)
⊕⊝⊝⊝
VERY LOW 5 6 7
Oral cryotherapy reduced the duration of TPN by 2.18 days.
There was some additional very low quality evidence, from a
single small study at high risk of bias, reporting only median,
range and P value, that oral cryotherapy reduced the number
of days of TPN (Additional Table 1)
Duration of
hospitalisa-
tion (days)
The mean du-
ration of hos-
pitalisation
(days) was 0
The mean dura-
tion of hospital-
isation (days) in
the intervention
group was 1.39
undefined few-
er (2.97 fewer to
0.19 more)
- 123
(2 RCTs)
⊕⊕⊝⊝
LOW 3 4
There is insufficient evidence to show that oral cryotherapy re-
duces the duration of hospitalisation. This is supported by ad-
ditional very low quality evidence, from a single small study at
high risk of bias, reporting only median, range and P value, that
there is insufficient evidence to show a reduction in this out-
come (Additional Table 1)
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; TPN: total parenteral nutrition
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 All 5 studies at risk of performance and detection bias, with 1 study at added risk of attrition bias
2 The I2 value indicates that a considerable amount (> 90%) of the variability in eEect estimates is due to heterogeneity rather than chance
3 Both studies at high risk of performance and detection bias
4 Low sample size from 2 small studies
5 Single study at high risk of performance and detection bias
6 Low sample size and wide confidence interval
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7 Indirect due to single study in 1 setting (in terms of country, healthcare system, and participants potentially diEering from other countries)
** There were no studies conducted on children
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B A C K G R O U N D
Description of the condition
Treating cancer with chemotherapy, radiotherapy of the head and
neck, or targeted therapy can cause toxic oral side eEects (Al-
Dasooqi 2013; Scully 2006; Sonis 2004). Perhaps the most widely
researched of these side eEects is oral mucositis (Al-Dasooqi 2013),
which aEects at least 75% of high risk patients (those receiving
head and neck radiotherapy or high-dose chemotherapy) (Scully
2006). Oral mucositis may be under-reported in lower risk groups
for various reasons: their tendency to be outpatients with less
observation; less reporting of moderate mucositis; or patients
and clinicians wishing to avoid any disruption to optimal cancer
treatment (Scully 2006).
Simply put, oral mucositis aEects the oral mucosa (the mucous
membrane of moist tissue lining the oral cavity) and can lead to the
development of lesions (ulcers). However, the process that leads to
oral mucositis is complex and multifactorial, with Sonis' five phase
model being the currently accepted explanation for the sequence
of events underlying the condition (Sonis 2004; Sonis 2009).
1. Initiation: DNA damage caused by chemotherapy or
radiotherapy results in the loss of ability to proliferate in the
basal cells of the epithelium (the external layers of cells lining
the oral mucosa). This produces reactive oxygen species (ROS).
2. Primary damage response: Radiotherapy, chemotherapy, ROS,
and DNA strand breaks all contribute to the activation of
transcription factors such as nuclear factor kappa beta (NF-Kβ),
and sphingomyelinases. All this leads to the upregulation of
pro-inflammatory cytokines (e.g. tumour necrosis factor alpha
- TNF-α), nitric oxide, ceramide, and matrix metalloproteinases,
resulting in the thinning of the epithelium through tissue injury
and cell death, culminating with the destruction of the oral
mucosa.
3. Signal amplification: Some of the molecules in the previous
phase can lead to the exacerbation and prolonging of tissue
injury through positive or negative feedback (e.g. TNF-α
can positively feedback on NF-Kβ thus inducing more pro-
inflammatory cytokine production).
4. Ulceration: Bacteria colonise ulcers and their cell wall products
infiltrate the submucosa (the connective tissues beneath the
oral mucosa), activating tissue macrophages (white blood
cells that respond to infection or damaged/dead cells), which
results in further production of pro-inflammatory cytokines,
inflammation, and pain.
5. Healing: Signalling from the extracellular matrix of the
submucosa results in epithelial proliferation and diEerentiation,
and thus a thickening of the epithelium. The local oral flora are
reinstated.
Understanding of the pathobiology leading to mucosal toxicity as
a result of targeted therapies (e.g. mammalian target of rapamycin
(mTOR) inhibitor-associated stomatitis - mIAS) is currently limited,
but it is thought to diEer from chemotherapy- and radiotherapy-
induced mucositis, and the clinical presentation of the ulcers is
more similar to aphthous stomatitis (Al-Dasooqi 2013; Boers-Doets
2013; Peterson 2015).
Chemotherapy-induced oral mucositis is regarded as an acute
condition, with ulceration normally occurring one week aNer
treatment, and resolving within three weeks of treatment (Sonis
2009). Radiotherapy-induced oral mucositis is chronic in nature,
with ulceration normally occurring around two weeks into a seven-
week treatment cycle, and resolving three to four weeks aNer
treatment has ended (Sonis 2009).
Ulceration is the most significant phase as it leads to pain of varying
severity, and diEiculties with eating, swallowing, and talking
(Scully 2006). This in turn leads to the consumption of pain relief
medication, requirement for nutritional support (e.g. a feeding
tube), treatment of the oral mucositis, specialist oral hygiene care,
increased medical appointments and use of staE and resources,
and, in some instances, hospitalisation (Jensen 2014; Miller 2001;
Trotti 2003). Thus the negative impact on the quality of life of cancer
patients, when they are already suEering, is severe (Elting 2008;
Epstein 1999). Further problems can occur in immunosuppressed
patients if whole bacteria on the ulcer surface cross into the
underlying submucosa, potentially leading to bacteraemia and
sepsis, which require antibiotics and hospitalisation, and can cause
death (Jensen 2014; Peterson 2015; Scully 2006).
Therefore, oral mucositis can be a dose-limiting condition,
disrupting a patient's optimal cancer treatment plan and
consequentially decreasing their chances of survival (Jensen 2014;
Peterson 2015; Sonis 2004). The additional costs associated with
oral mucositis can be significant, with one study reporting a median
incremental cost of USD 18,515 per patient (Nonzee 2008). These
costs have been reported to be as much as USD 42,749 more per
patient when ulcerative oral mucositis is present (Sonis 2001).
Description of the intervention
Fluorouracil (5FU) is a common chemotherapy treatment for solid
cancers and, in this setting, oral cryotherapy typically involves
placing ice chips in the mouth five minutes prior to chemotherapy
and continuing for 30 minutes (Lalla 2008). In other settings,
such as patients with haematological cancers receiving high-dose
melphalan prior to stem cell transplantation, oral cryotherapy is
administered for longer periods of time, even as long as seven hours
(Lilleby 2006). The ice chips are typically rounded to avoid any sharp
edges or corners that may cause irritation to the patient, and also
so that they can be easily moved around in the mouth (Karagözoğlu
2005).
The advantages of using cryotherapy over other interventions
are its availability, cost-eEectiveness, ease of administration, and
safety (in terms of lack of side-eEects), and that it is well tolerated
by patients (Peterson 2013).
How the intervention might work
The use of ice chips in the mouth cools the oral tissues and causes
the blood vessels to narrow (vasoconstriction), thus reducing
blood flow to the area and therefore also restricting the amounts
of the chemotherapy drugs delivered to the tissues (Lalla 2008;
Peterson 2013; Scully 2006). Cryotherapy may only be eEective in
the prevention of oral mucositis in patients receiving chemotherapy
drugs that have a short half-life, such as bolus 5-FU, bolus
edatrexate, and high-dose melphalan (Lalla 2008; Peterson 2013;
Scully 2006). Considering the mechanism by which cryotherapy
can prevent oral mucositis caused by chemotherapy, it is unclear
whether or not it could have any eEect on oral mucositis caused
by radiotherapy (Lalla 2008). It is also unclear whether or not
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cryotherapy could have any role in the prevention of targeted
therapy-induced stomatitis.
Why it is important to do this review
This review is the first of a series that will replace the previously
published Cochrane review covering all interventions for the
prevention of oral mucositis in patients with cancer receiving
treatment (Worthington 2011). The Mucositis Study Group (MSG)
of the Multinational Association of Supportive Care in Cancer/
International Society of Oral Oncology (MASCC/ISOO) is a group
that was set up in 1998 for the purpose of producing international
evidence-based clinical practice guidelines for managing mucositis
(both oral and gastrointestinal), which they first published in 2004,
with the latest update published in 2014 (Lalla 2014). In order to
facilitate the future updating of Cochrane reviews on this topic, and
also to make them more usable to clinicians, guideline developers,
and consumers, we have decided to divide the original Cochrane
review into the same intervention categories as those used by
MASCC/ISOO, which are as follows:
• basic oral care/good clinical practice;
• growth factors and cytokines;
• anti-inflammatory agents;
• antimicrobials, mucosal coating agents, anaesthetics, and
analgesics;
• laser and other light therapy;
• cryotherapy;
• natural and miscellaneous agents;
• amifostine.
We believe that running in tandem with the MASCC/ISOO categories
will enable the Cochrane reviews to more easily feed into such
guidelines. We will also be able to be more thorough and rigorous
in our assessment and summarising of the evidence in each of
the categories, which was not feasible in a single Cochrane review
approaching 150 included studies.
It is also important to do this review as it is consistently shown to be
the most used review produced by the Cochrane Oral Health Group
(in terms of full-text downloads). It was also ranked by an expert
panel of oral medicine specialists as being the most important
topic in the field of oral medicine in an international prioritisation
exercise carried out by the Cochrane Oral Health Group in 2014
(Worthington 2015).
O B J E C T I V E S
To assess the eEects of oral cryotherapy for preventing oral
mucositis in patients with cancer who are receiving treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) of parallel
design. It is possible to conduct cross-over studies in this area
as patients may receive several treatment sessions, with any
mucositis completely healing in the periods between the sessions.
However, we did not include cross-over data as we cannot discount
any period eEects, with mucositis risk increasing as patients receive
further cycles of treatment (Scully 2006; Sonis 2009). Instead, we
used the first-period data only and treated such studies as parallel
studies.
Types of participants
We included all patients with cancer who are receiving treatment.
Types of interventions
We included studies comparing oral cryotherapy for the prevention
of oral mucositis against usual care, no treatment, or any other
treatment to prevent oral mucositis. We also included studies
comparing diEerent regimens of oral cryotherapy against each
other (head-to-head studies). We planned to include studies of
oral mucositis caused by chemotherapy, radiotherapy, and targeted
therapy.
We excluded studies with 'complex' interventions for the
prevention of mucositis, such as lasers plus cryotherapy versus
lasers. We excluded studies assessing diEerent cancer treatments
where the primary outcome is survival/cure, with mucositis as a
toxicity.
Types of outcome measures
We are in agreement with Williamson 2012 that, if clinical trials
and systematic reviews are to be utilised, the outcomes assessed
should be those considered important to patients, healthcare
professionals, and other key stakeholders. If outcomes and
outcome measures are inconsistent across studies, it will not
be possible to compare and summarise research, and there is
potential for outcome reporting bias, with the selective reporting
of results based on statistical significance and favourability (Clarke
2007; Dwan 2008; Williamson 2005). This can lead to exaggerated
estimates of eEect in systematic reviews of interventions, leading
to an incorrect belief that an intervention is more beneficial that
it truly is (Clarke 2007). It is thought that the way to address this
problem is to develop disease- or condition-specific core outcome
sets to be used as a minimum when conducting and reporting
clinical trials (Clarke 2007; Williamson 2012).
Therefore we used the core outcome set produced by Bellm 2002,
which is registered on the COMET (Core Outcome Measures in
EEectiveness Trials) Initiative's website (www.comet-initiative.org),
and is the only core outcome set for oral mucositis known to us.
Primary outcomes
Mucositis incidence of any severity. We used mucositis measured
on a 0 to 4 point scale (none to severe) and dichotomised it as any
mucositis (0 versus 1+), moderate to severe mucositis (0 to 1 versus
2+), and severe mucositis (0 to 2 versus 3+).
Some studies measure mucositis using a composite scale. If it was
possible to extract the 'mucositis only' data from the total score, we
would have included the data in the analyses. If it was not possible,
we would have recorded the composite data in an additional table.
Secondary outcomes
• Interruptions to cancer treatment.
• Oral pain.
• Quality of life.
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• Normalcy of diet (including use of percutaneous endoscopic
gastrostomy (PEG) feeding tubes or total parenteral nutrition
(TPN)).
• Adverse events.
• Number of days in hospital.
• Number of days of treatment with opioid analgesics.
• Number of days unable to take medicine orally.
Search methods for identification of studies
For the identification of studies included or considered for this
review, we developed detailed search strategies for each database
searched. These were based on the search strategy we developed
for MEDLINE (Ovid) (Appendix 3), which we revised appropriately
for each database. The study design filter used by the Cochrane Oral
Health Group was added to the search of the EMBASE database to
limit the search to randomised controlled trials (Appendix 4).
Electronic searches
We searched the following electronic databases:
• the Cochrane Oral Health Group Trials Register (to 17 June 2015)
(Appendix 1);
• the Cochrane Central Register of Controlled Trials (CENTRAL)
(Cochrane Library 2015, Issue 5) (Appendix 2);
• MEDLINE via Ovid (1946 to 17 June 2015) (Appendix 3);
• EMBASE via Ovid (1980 to 17 June 2015) (Appendix 4);
• CANCERLIT via PubMed (1950 to 17 June 2015) (Appendix 5);
• CINAHL via EBSCO (1937 to 17 June 2015) (Appendix 6).
No restrictions were placed on the language or date of publication
when searching the electronic databases.
Searching other resources
We searched the following databases for ongoing trials (Appendix
7):
• US National Institutes of Health Trials Registry (http://
clinicaltrials.gov) (to 17 June 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (http://apps.who.int/trialsearch/
default.aspx) (to 17 June 2015).
We only included handsearching done as part of the Cochrane
Worldwide Handsearching Programme and uploaded to CENTRAL.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and
abstracts retrieved from the electronic searches. We obtained full-
text copies of all studies that appeared to meet the inclusion
criteria of the review, or where there was insuEicient information
in the title or abstract to make a clear judgement. Two review
authors independently assessed the full text copies for eligibility
and attempted to resolve any disagreements through discussion.
We consulted a third review author if we could not resolve
disagreements.
On assessing the full text article, we discarded any studies that
clearly did not meet the inclusion criteria. We recorded all other
studies that did not meet the inclusion criteria, along with reasons
for exclusion, in the Characteristics of excluded studies table.
Data extraction and management
Two review authors independently extracted the data from each
included study using a specially designed data extraction form,
which we first piloted on a small sample of studies. We contacted
study authors for clarification or missing data where necessary
and feasible. We resolved any disagreements through discussion,
consulting a third review author to achieve consensus when
necessary.
We recorded the following data for each included study in the
Characteristics of included studies table.
• Trial design, location, number of centres, recruitment period.
• Inclusion/exclusion criteria, age and gender of participants,
number randomised/analysed, any other potentially important
prognostic factors (e.g. cancer type, cancer treatment, etc.).
• Detailed description of the intervention and comparator,
including timing and duration. Information on compliance with
the cryotherapy regimen.
• Details of the outcomes reported, including method of
assessment and time(s) assessed.
• Details of sample size calculations, adverse eEects, funding
sources, declarations/conflicts of interest.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of
each included study using the Cochrane domain-based, two-part
tool as described in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We contacted
study authors for clarification or missing information where
necessary and feasible. We resolved any disagreements through
discussion, consulting a third review author to achieve consensus
when necessary.
We completed a 'Risk of bias' table for each included study. For
each domain of risk of bias, we first described what was reported
to have happened in the study. This provided the rationale for our
judgement of whether that domain was at low, high, or unclear risk
of bias.
We assessed the following domains:
1. sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
4. blinding of outcome assessment (detection bias);
5. incomplete outcome data (attrition bias);
6. selective outcome reporting (reporting bias);
7. other bias.
We categorised the overall risk of bias of individual studies. Studies
were categorised as being at low, high, or unclear risk of bias
according to the following criteria:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains were at low risk of bias;
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• high risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains were at high
risk of bias; or
• unclear risk of bias (plausible bias that raises some doubt about
the results) if one or more domains were at unclear risk of bias.
We also presented the 'Risk of bias' summary graphically (Figure 1).
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Figure 1.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 1.   (Continued)
 
Measures of treatment e=ect
For continuous outcomes (e.g. oral pain on a visual analogue scale)
where studies used the same scale, we used the mean values and
standard deviations (SDs) reported in the studies in order to express
the estimate of eEect as mean diEerence (MD) with 95% confidence
interval (CI). Where diEerent scales were used, we would have
considered expressing the treatment eEect as standardised mean
diEerence (SMD) with 95% CI.
For dichotomous outcomes (e.g. mucositis of any severity/no
mucositis), we expressed the estimate of eEect as a risk ratio (RR)
with 95% CI.
Unit of analysis issues
The participant was the unit of analysis.
Dealing with missing data
We attempted to contact the author(s) of all included studies, where
feasible, for clarification, missing data, and details of any other
outcomes that may have been measured but not reported. We used
the methods described in Section 7.7.3 of the Cochrane Handbook
for Systematic Reviews of Interventions to estimate missing SDs
(Higgins 2011). We did not use any other statistical methods or
perform any further imputation to account for missing data.
Assessment of heterogeneity
When a suEicient number of studies were included in any meta-
analyses, we assessed clinical heterogeneity by examining the
characteristics of the studies, the similarity between the types
of participants, the interventions, and the outcomes. We also
assessed heterogeneity statistically using a Chi2 test, where a
P value < 0.1 indicates statistically significant heterogeneity.
We quantified heterogeneity using the I2 statistic. A guide to
interpretation of the I2 statistic given in Section 9.5.2 of the
Cochrane Handbook for Systematic Reviews of Interventions is as
follows (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
If at least 10 studies were included in a meta-analysis, we planned
to assess publication bias according to the recommendations on
testing for funnel plot asymmetry (Egger 1997), as described in
Section 10.4 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). If asymmetry was identified, we would
examine possible causes. We were not able to assess publication
bias in this way because, although we had a suEicient number of
studies in our meta-analyses for the primary outcome, they were
split into subgroups containing less than 10 studies, with no pooling
of the subgroup totals.
Data synthesis
We only carried out meta-analyses where there were studies of
similar comparisons reporting the same outcomes. We combined
MDs for continuous data, and RRs for dichotomous data. Our
general approach was to use a random-eEects model. With this
approach, the CIs for the average intervention eEect were wider
than those that would have been obtained using a fixed-eEect
approach, leading to a more conservative interpretation.
We used an additional table to report the results from studies not
suitable for inclusion in a meta-analysis.
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analyses according to type of cancer
treatment. We stated in the protocol that we would also use
both type of cancer treatment and cancer type as categories for
subgroup analyses. However, these categories are very closely
related, so it did not make sense to do so. We also would have
considered age group (children versus adults) as a category for
subgroup analyses, if there had been suEicient numbers of studies
with these diEering populations.
Sensitivity analysis
As all studies were at high risk of both performance and detection
bias, it was not possible to test the robustness of our results by
performing sensitivity analyses based on excluding the studies at
unclear or high risk of bias from the analyses.
If any meta-analyses had included several small studies and a
single very large study, we would have undertaken a sensitivity
analysis comparing the eEect estimates from both random-eEects
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and fixed-eEect models. If these were diEerent we would have
reported on both analyses as part of the results section, and we
would have considered possible interpretation.
Presentation of main results
We produced a 'Summary of findings' table for each comparison
that included more than one study, and for the main outcomes
(listed below). We produced a separate table for each of the two
main cancer treatment types in this review: treatment of solid
cancers and treatment of haematological cancers. We used GRADE
methods (GRADE 2004), and GRADEpro 2014 soNware. We assessed
the quality of the body of evidence for each comparison and
outcome by considering the overall risk of bias of the included
studies, the directness of the evidence, the inconsistency of the
results, the precision of the estimates, and the risk of publication
bias. We categorised the quality of each body of evidence as high,
moderate, low, or very low.
Main outcomes:
• mucositis incidence;
• interruptions to cancer treatment;
• oral pain;
• quality of life;
• normalcy of diet;
• adverse events;
• number of days in hospital.
R E S U L T S
Description of studies
Results of the search
The electronic searches retrieved 745 references to studies. ANer
removing duplicates, this figure was reduced to 426. We examined
the titles and abstracts of these references and discarded all but 40
with no further assessment. Where possible, we obtained full-text
copies of these 40 potentially relevant references, and we linked
any multiple references to the same study under a single study
ID, resulting in a total of 32 studies. We excluded 11 studies (11
references) at this stage. The remaining 21 studies (29 references)
appeared to meet our inclusion criteria and we were able to include
14 of these studies (20 references). Of the remaining 7 studies (9
references), 5 studies (7 references) are awaiting assessment due
to insuEicient information in the abstract or trials registry record
to allow inclusion in the review, and 2 studies (2 references) are
ongoing. We present this process as a flow chart in Figure 2.
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Figure 2.   Study flow diagram
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Figure 2.   (Continued)
 
Included studies
Fourteen studies were included in this review (see Characteristics
of included studies tables).
Characteristics of the trial designs and settings
Twelve studies were of parallel design, with the remaining two
studies using a cross-over design (Mahood 1991; Rocke 1993). We
treated the cross-over studies as parallel studies by using only
the first-period data. Eleven studies had two arms, whilst two
studies had three arms (Sorensen 2008; Toro 2013), one of which
was excluded from Toro 2013 as we felt that the comparison of
the third group, using supersaturated calcium phosphate rinse
(Caphosol®), with the co-intervention of cryotherapy plus saline
may be confounded. Another study had four arms, with one of
those arms being excluded from this review because it involved
treating oral mucositis rather than preventing it (Zhang 2011).
Four studies were conducted in the USA (Lilleby 2006; Mahood
1991; Rocke 1993; Toro 2013), three in Iran (Askarifar 2015; Heydari
2012; Kakoei 2013), two in Italy (Cascinu 1994; Gori 2007), and
one in each of Turkey (Katranci 2012), Canada (Salvador 2012),
Denmark (Sorensen 2008), Sweden (Svanberg 2007), and China
(Zhang 2011). There were nine single-centre studies, one with two
centres (Heydari 2012), and four that were multicentre but were
unclear about how many centres were involved (Gori 2007; Mahood
1991; Rocke 1993; Sorensen 2008). Five studies did not report the
duration of the trial from start to finish, but the remaining studies
ranged in total duration from six months to five years.
Eight studies reported details of a sample size calculation: two of
these studies achieved their required sample size (Kakoei 2013;
Salvador 2012), two did not (Sorensen 2008; Toro 2013), three
were unclear whether or not the sample size requirements were
met (Askarifar 2015; Gori 2007; Lilleby 2006), and the remaining
study did not use the primary outcome of oral mucositis incidence/
severity to calculate the required sample size (Svanberg 2007). Six
studies did not mention sample size calculation (Cascinu 1994;
Heydari 2012; Katranci 2012; Mahood 1991; Rocke 1993; Zhang
2011).
Eleven studies reported on funding sources, all of which were in
the form of independent funding from government, charities or
universities. The remaining three studies did not report any funding
sources (Cascinu 1994; Katranci 2012; Zhang 2011). Four studies
declared that there were no conflicts of interest (Askarifar 2015;
Katranci 2012; Salvador 2012; Toro 2013), whilst the other ten
studies did not mention conflicts of interest.
Characteristics of the participants
There were 1316 participants randomised to interventions
(including only the intervention groups relevant to this review), of
which 1280 were included in the studies' analyses. Age ranged from
8 to 85 years across the studies, with mean or median ages ranging
between 36 to 63 years. However, only one study reported the
inclusion of children, although this was a small minority (Gori 2007).
In general, there were more males than females in the studies.
Only one study included more females than males, but this was
because 50% of the participants had breast cancer (Heydari 2012).
One study involved participants undergoing radiotherapy to the
head and neck, with the remaining studies involving participants
undergoing chemotherapy. No studies involved targeted therapy.
Solid cancers
In eight studies, the participants had solid cancers. In four of these
studies, the majority of cancers were gastrointestinal, colorectal,
and breast (Cascinu 1994; Heydari 2012; Katranci 2012; Sorensen
2008), whilst two studies did not state the types of cancers involved
(Mahood 1991; Rocke 1993), one study included only head and
neck cancers (Kakoei 2013), and one study included only bone
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cancer (osteosarcoma) (Zhang 2011). The cancer treatment in
these studies of solid cancers mostly involved fluorouracil (5FU),
normally in conjunction with leucovorin (Cascinu 1994; Heydari
2012; Katranci 2012; Mahood 1991; Rocke 1993; Sorensen 2008).
The study on participants with head and neck cancers was the
only study included in this review that assessed the eEects of
oral cryotherapy for preventing oral mucositis in people receiving
radiotherapy-only (Kakoei 2013). In the remaining study including
participants with osteosarcoma (Zhang 2011), the cancer treatment
was high-dose methotrexate plus vincristine and leucovorin.
Haematological cancers
In five studies, the participants had haematological cancers:
multiple myeloma (Lilleby 2006; Salvador 2012; Toro 2013),
Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple
myeloma (Askarifar 2015), and mixed (Gori 2007). The cancer
treatment in these studies involved high-dose melphalan (Askarifar
2015; Lilleby 2006; Salvador 2012; Toro 2013), or low-dose
methotrexate for preventing graN-versus-host disease (GVHD),
which is the rejection of donor cells, aNer allogeneic (cells from a
donor) stem cell transplantation (Gori 2007).
One study included one participant in each group (2.6%) with solid
cancer (testicular), with the remaining participants all having a
mixture of haematological cancers (Svanberg 2007). The cancer
treatment in this study was mixed, with the majority (73%) of
participants receiving either high-dose melphalan or BEAC regimen
(carmustine, etoposide, cytarabine and cyclophosphamide).
In these six studies involving haematological cancers, participants
also had haematopoietic stem cell transplantation (HSCT)
following chemotherapy. However, in Gori 2007, the authors
assessed the eEects of oral cryotherapy for preventing oral
mucositis due to further chemotherapy given aNer HSCT for the
purpose of preventing GVHD.
Characteristics of the interventions and comparisons
One study compared diEerent durations (30 minutes versus 60
minutes) of oral cryotherapy (Rocke 1993). Eight studies compared
oral cryotherapy against no treatment (Cascinu 1994; Gori 2007;
Heydari 2012; Kakoei 2013; Mahood 1991; Salvador 2012; Svanberg
2007; Toro 2013). In four of these studies, both the oral cryotherapy
group and control group received standard oral care (Kakoei 2013;
Salvador 2012; Svanberg 2007; Toro 2013), so the comparison
can be thought of as being oral cryotherapy versus no treatment
(no extra treatment). One of these four studies also had a
supersaturated calcium phosphate rinse (Caphosol®) group which
we excluded from this review because we did not consider this
intervention versus cryotherapy plus saline rinse to be an eligible
comparison, due to potential confounding from the latter co-
intervention (Toro 2013). Another four studies compared oral
cryotherapy against some form of standard oral care: saline
rinse (Askarifar 2015; Lilleby 2006; Sorensen 2008), unspecified
(Katranci 2012). One of these studies had a third intervention group
that received chlorhexidine rinse (Sorensen 2008). The remaining
study had three eligible intervention groups and compared oral
cryotherapy against leucovorin rinse and high-dose leucovorin
rinse (Zhang 2011).
Most studies used ice chips for cooling the oral cavity, with one
study also allowing an alternative option of using popsicles (a
flavoured ice lolly) (Gori 2007), and another study allowed the
alternative option of ice-cold water (Svanberg 2007). Two studies
used ice cubes (Askarifar 2015; Kakoei 2013), possibly suggesting a
larger size of ice pieces, whereas another two studies used crushed
ice (Sorensen 2008; Toro 2013), possibly suggesting smaller ice
pieces. One study exclusively used ice water (Zhang 2011).
The duration of treatment with oral cryotherapy varied widely
according to chemotherapy regimen, and was unclear in five
studies (Askarifar 2015; Cascinu 1994; Svanberg 2007; Toro 2013;
Zhang 2011). The most consistent cryotherapy schedule was in
those participants receiving fluorouracil (5FU) and leucovorin, and
typically consisted of 30 minutes (45 minutes in Sorensen 2008;
60 minutes in half the participants in Rocke 1993) per day for five
consecutive days. The longest duration of oral cryotherapy was
seven hours (Lilleby 2006).
Characteristics of the outcomes
We wrote to authors of 11 of the included studies to ask if they had
measured any other outcomes than those mentioned in the study
reports. We did not write to authors of three of the included studies
as they were published before the year 2000 and we thought it was
unfeasible to obtain any extra data (Cascinu 1994; Mahood 1991;
Rocke 1993). The authors of one study have since provided us with
data for two outcomes not reported in their study: 'interruptions to
cancer treatment' and 'oral pain' (Heydari 2012).
Primary outcome
For the primary outcome of oral mucositis, we were interested in
both the presence/absence of oral mucositis, and also diEerent
levels of severity. All 14 included studies measured oral mucositis.
Eleven studies used the WHO 0 to 4 scale, or a scale based on this.
Three studies used the National Cancer Institute common toxicity
criteria (NCI-CTC) 0 to 4 scale (Lilleby 2006; Sorensen 2008; Zhang
2011). The WHO and NCI-CTC scales include both subjective and
objective elements, and are highly comparable (Appendix 8), such
that it is not necessary to use standardised mean diEerence when
including both types of measurement in a meta-analysis. One study
used a modified version of the Oral Mucositis Assessment Scale
(OMAS) as the primary tool for measurement of oral mucositis, but
provided us with full data according to the WHO scale (Svanberg
2007). The OMAS is an objective scale, measuring ulceration (0 to 3
scale) and erythema (0 to 2 scale) at nine diEerent sites in the oral
cavity (Appendix 8).
Eight studies reported the data in our preferred format which was
the maximum oral mucositis score, on a 0 to 4 scale, experienced
by each participant over the length of the study (Cascinu 1994;
Gori 2007; Heydari 2012; Lilleby 2006; Mahood 1991; Rocke 1993;
Sorensen 2008; Toro 2013). One study reported the incidence of
any oral mucositis (i.e. grades 1 to 4), but appeared to selectively
report the incidence of each grade on a single day quite early
in the study (i.e. not the maximum score experienced by each
participant over the length of the study) (Zhang 2011). Four studies
reported the mean oral mucositis score on multiple assessment
days (Askarifar 2015; Kakoei 2013; Salvador 2012; Svanberg 2007),
whilst the remaining study reported the incidence of each oral
mucositis grade on multiple assessment days (Katranci 2012).
We wrote to all authors who reported means or on multiple
assessment days or both, to request incidence data in the form of
a single table reporting the maximum oral mucositis score (on a
0 to 4 scale) experienced by each participant over the length of
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the study. The authors of two studies supplied us with the data
in this format (Salvador 2012; Svanberg 2007), and another author
supplied us with incidence data, but on multiple assessment days
(Askarifar 2015). We decided to use the data on the day with the
highest incidence of grades > 0 (day 7) because, in this study, this
probably most closely equates to the maximum score experienced
per participant (as reported in the majority of other studies in
the meta-analyses). For the other study reporting incidence data
(Katranci 2012), but on multiple assessment days, we received no
response from the authors, so we again used the data on the day
with the highest incidence of grades > 0 (day 14), although we are
not sure how valid this is because there was still a high incidence
of severe oral mucositis at day 21. For mean scores on multiple
assessment days, we used the day with the highest control group
mean and recorded the results in an additional table.
The majority of studies assessed oral mucositis at multiple
timepoints over approximately four weeks (Cascinu 1994; Gori
2007; Lilleby 2006; Mahood 1991; Rocke 1993; Sorensen 2008;
Toro 2013), with some assessing it at multiple timepoints over
three weeks (Askarifar 2015; Heydari 2012; Katranci 2012; Svanberg
2007), and the remaining studies assessing it at multiple timepoints
over 10 to 14 days (Kakoei 2013; Salvador 2012; Zhang 2011). Where
participants had multiple cycles of treatment, we only reported the
results for the first cycle.
When studies reported oral mucositis data assessed separately
by physicians and participants, we generally chose to use the
physician-judgement as we felt that this may be the more objective
of the two, and therefore potentially less biased. There was one
exception where only the participant-judged data was reported in
the study as there was no significant diEerence between that and
the physician-judgement (Sorensen 2008).
To summarise, we were able to include the primary outcome data
for 13 of the included studies: 11 in the comparison of cryotherapy
versus control (Askarifar 2015; Cascinu 1994; Gori 2007; Heydari
2012; Katranci 2012; Lilleby 2006; Mahood 1991; Salvador 2012;
Sorensen 2008; Svanberg 2007; Toro 2013); one in the comparison
of diEerent durations of cryotherapy (Rocke 1993); and one in the
comparison of cryotherapy versus leucovorin rinses (Zhang 2011).
Secondary outcomes
Interruptions to cancer treatment
No studies reported this important outcome, but the authors of one
study responded to our email request and provided us with both
dichotomous (event) data and continuous data, the latter in the
form of 'days of interruption' (Heydari 2012).
Oral pain
Four studies reported oral pain (Kakoei 2013; Lilleby 2006; Salvador
2012; Svanberg 2007), another study measured oral pain but the
study report is currently being written and the data are undergoing
analysis (Toro 2013), and the authors of a further study responded
to our email request and provided us with oral pain data (Heydari
2012). Only two of these five studies reported data that we were
able to combine in a meta-analysis (Lilleby 2006; Salvador 2012),
which was the mean oral pain score on a 0 to 10 scale for the study
period. Another study also measured oral pain on a 0 to 10 scale,
but did not report any usable data in the form of mean and standard
deviation for the study period (Svanberg 2007). One study reported
mean pain scores on multiple assessment days but did not describe
the scale used, and therefore we were unable to use the data for
meta-analysis (Kakoei 2013). The authors of one study provided us
with data measured on a 1 to 5 scale representing the duration of
time for which pain was experienced, unlike the other studies where
the score represented pain intensity (Heydari 2012). We decided
to present these data in an additional table. It is not clear what
scale was used in the remaining study for which the data are not yet
available (Toro 2013).
Quality of life
No studies reported this outcome. The authors of one study have
confirmed that quality of life was measured using the Patient-
Reported Oral Mucositis Symptom (PROMS) scale, but the data are
currently unavailable as the study report and analysis have not yet
been completed (Toro 2013).
Normalcy of diet
Two studies reported the duration, measured in days, of total
parenteral nutrition (TPN) (Lilleby 2006; Svanberg 2007). However,
one of these studies reported a median and range for each group,
rather than mean and standard deviation, so we were unable to
use the data in our analysis (Lilleby 2006). Another study reported
the functional intake of food and fluids on a 1 to 5 scale, but we
were unable to use the data that were presented in a mixed-eEect
regression model (Salvador 2012).
Adverse events
It was diEicult to assess adverse eEects in many cases due
to the diEiculty to distinguish between eEects caused by oral
cryotherapy and those caused by various cancer treatments. It
also did not make sense to formally meta-analyse data from
comparisons of oral cryotherapy with no treatment. Furthermore,
in the context of cancer treatment, and with no serious eEects being
expected from sucking ice, we considered this outcome to be of
limited importance in this particular review (whereas it may be
more important in our reviews of other potentially more harmful
interventions for preventing oral mucositis e.g. growth factors
and cytokines). We therefore decided to report this outcome in a
narrative format.
Four studies did not mention adverse eEects (Askarifar 2015; Gori
2007; Kakoei 2013; Zhang 2011), whilst the quality of reporting for
this outcome varied between the remaining nine studies.
Number of days in hospital
Three studies reported this outcome (Lilleby 2006; Salvador 2012;
Svanberg 2007). We were able to combine the data for two studies,
but the third study reported the median and range for each group,
and we were therefore unable to use the data (Lilleby 2006).
Number of days of treatment with opioid analgesics
Two studies reported this outcome (Lilleby 2006; Svanberg 2007),
but one reported the median and range for each group, and we were
therefore unable to use the data (Lilleby 2006). A further study has
measured 'narcotic use' but the data are currently unavailable as
the study report and analysis have not yet been completed, and we
do not know how this outcome was measured (Toro 2013).
Number of days unable to take medicine orally
No studies reported this outcome.
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Excluded studies
We excluded 11 studies from this review for the following reasons.
• Not a randomised controlled trial (RCT): non-random allocation
to groups (Karagozoglu 2005; Papadeas 2007; Sato 2006); used
historical controls (Aisa 2005; Mori 2006); translation to English
confirmed it was case series (Ohyama 1994).
• Unclear if RCT and authors have not provided clarification (Sato
1997).
• Cross-over study with no reporting of first-period data (Baydar
2005; Castelino 2011; Nikoletti 2005).
• Confounding due to co-interventions and therefore not possible
to attribute eEect to cryotherapy (de Paula Eduardo 2014).
Risk of bias in included studies
Allocation
Random sequence generation
Eight studies described an adequate method of random sequence
generation (Askarifar 2015; Gori 2007; Heydari 2012; Kakoei 2013;
Katranci 2012; Salvador 2012; Svanberg 2007; Zhang 2011), and
the authors of three further studies responded to our requests for
further information (Cascinu 1994; Lilleby 2006; Toro 2013), which
clarified that their methods were adequate. Therefore we assessed
11 studies as being at low risk of bias for this domain. The remaining
three studies only stated that participants were randomised but
did not describe their methods, so they were assessed as being
at unclear risk of bias for this domain (Mahood 1991; Rocke 1993;
Sorensen 2008).
Allocation concealment
Two studies provided details of how the random sequence was
concealed from those involved in the study (Salvador 2012;
Svanberg 2007), with a further five studies providing details
through correspondence (Askarifar 2015; Cascinu 1994; Heydari
2012; Lilleby 2006; Toro 2013). Therefore we assessed seven studies
as being at low risk of bias for this domain. The remaining seven
studies did not mention any methods used to conceal the random
sequence, and we assessed them as being at unclear risk of bias
(Gori 2007; Kakoei 2013; Katranci 2012; Mahood 1991; Rocke 1993;
Sorensen 2008; Zhang 2011).
Overall, seven studies are at low risk of selection bias, meaning that
we assessed both of the above domains as being at low risk of bias
(Askarifar 2015; Cascinu 1994; Heydari 2012; Lilleby 2006; Salvador
2012; Svanberg 2007; Toro 2013). The remaining seven studies are
at unclear risk of selection bias because one or both of the above
domains were rated as unclear (Gori 2007; Kakoei 2013; Katranci
2012; Mahood 1991; Rocke 1993; Sorensen 2008; Zhang 2011).
Blinding
Blinding of participants and personnel (performance bias)
It is not possible to blind participants or personnel to whether or
not oral cryotherapy has been allocated. Knowledge of treatment
allocation could aEect expectations and behaviours (e.g. control
group participants may take other interventions). Therefore we
judged all 14 studies to be at high risk of performance bias.
Blinding of outcome assessment (detection bias)
The subjective elements involved in the World Health Organisation
(WHO) and National Cancer Institute common toxicity criteria (NCI-
CTC) tools, which were used to measure oral mucositis in the
studies included in this review (Appendix 8), require the patient's
assessment of pain/soreness and their ability to swallow. Even if
blinding of outcome assessment is attempted, we do not believe it
is feasible. Therefore we judged all 14 studies to be at high risk of
detection bias.
Incomplete outcome data
Only two studies were at high risk of attrition bias (Askarifar 2015;
Sorensen 2008), both due to diEerential attrition between groups,
which may have been linked to prognosis. The remaining 12 studies
had negligible or no attrition and we assessed them as being at low
risk of attrition bias.
Selective reporting
Three studies were at high risk of selective reporting bias. One
of these studies reported oral pain, which was not stated in the
trials registry record or the methods section of the study report
(Kakoei 2013). It is possible that the decision to report this outcome
was based on statistical significance. Another study stated only
that there was no significant diEerences for oral pain, but reported
no data (Svanberg 2007). The remaining study only reported the
incidence of each grade of oral mucositis on day 4, despite stating
that it was measured on the day of chemotherapy and day 10
(Zhang 2011). We assessed the other 11 studies as being at low risk
of selective reporting bias as we could detect no obvious problems.
Other potential sources of bias
We did not consider there to be any issues arising from other
potential sources of bias in any of the studies and we therefore
assessed them all as being at low risk of bias for this domain.
Overall risk of bias
All fourteen studies were assessed as being at high overall risk of
bias (Figure 1).
E=ects of interventions
See: Summary of findings for the main comparison Cryotherapy
versus control for preventing oral mucositis in adults receiving
fluorouracil-based treatment for solid cancers; Summary of
findings 2 Cryotherapy versus control for preventing oral mucositis
in adults receiving high-dose melphalan-based treatment prior
to haematopoietic stem cell transplantation for haematological
cancers
Comparison 1: Cryotherapy versus control (standard care or no
treatment)
Oral mucositis (any)
Fluorouracil (5FU) treatment for solid cancers
Five studies (Cascinu 1994; Heydari 2012; Katranci 2012; Mahood
1991; Sorensen 2008), all at high risk of bias and analysing 444
participants, were combined in a meta-analysis which showed that
oral cryotherapy reduced the risk of developing oral mucositis
(risk ratio (RR) 0.61, 95% confidence interval (CI) 0.52 to 0.72, P
< 0.00001) when compared to control (Analysis 1.1). There was
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no heterogeneity in this eEect estimate (I2 = 0%). This can be
interpreted as a 39% (95% CI 28% to 48%) reduction in the risk of
developing oral mucositis associated with oral cryotherapy. Or in
other words, 4 people (95% CI 3 to 5 people) would need to receive
oral cryotherapy in order to prevent one additional person from
developing oral mucositis.
High-dose melphalan-based treatment prior to stem cell
transplantation
Five studies (Askarifar 2015; Lilleby 2006; Salvador 2012; Svanberg
2007; Toro 2013), all at high risk of bias and analysing 270
participants, were combined in a meta-analysis. There is evidence
to show that oral cryotherapy reduced the risk of developing
oral mucositis (RR 0.59, 95% CI 0.35 to 1.01, P = 0.05) when
compared to control (Analysis 1.1). Oral cryotherapy reduced the
risk of developing oral mucositis by 41% although the uncertainty
surrounding this eEect estimate means that the 95% CI ranges from
a 65% reduction to a 1% increase in risk. We would need to treat
3 people with oral cryotherapy to prevent one additional person
from developing oral mucositis. The confidence interval ranges
from 2 people needing to receive oral cryotherapy to prevent one
additional person from developing oral mucositis, to 111 people
needing to receive oral cryotherapy for one additional person
to develop oral mucositis. There was considerable heterogeneity
associated with this eEect estimate (I2 = 95%), although the reason/
s for this inconsistency is/are not clear on investigation of the
characteristics of the studies, in terms of the participants, settings,
methods, and interventions.
Methotrexate treatment post-stem cell transplantation to prevent
graJ versus host disease
One study (Gori 2007), at high risk of bias and analysing
122 participants, showed that there is insuEicient evidence to
determine whether or not oral cryotherapy reduces the risk of
developing oral mucositis (RR 0.98, 95% CI 0.90 to 1.07, P = 0.73)
when compared to control (Analysis 1.1).
Radiotherapy to the head and neck
One study (Kakoei 2013), at high risk of bias and analysing
40 participants, showed that there is insuEicient evidence to
determine whether or not oral cryotherapy reduces the mean
severity of oral mucositis 14 days aNer radiotherapy (mean
diEerence (MD) -0.25, 95% CI -0.72 to 0.22, P = 0.29) when compared
to control (Additional Table 1).
Oral mucositis (moderate to severe)
Fluorouracil (5FU) treatment for solid cancers
The same five studies (Cascinu 1994; Heydari 2012; Katranci 2012;
Mahood 1991; Sorensen 2008), when combined, showed that oral
cryotherapy reduced the risk of developing moderate to severe oral
mucositis (RR 0.52, 95% CI 0.41 to 0.65, P < 0.00001) when compared
to control (Analysis 1.2). There was no heterogeneity (I2 = 0%). Oral
cryotherapy reduced the risk of developing moderate to severe oral
mucositis by 48% (95% CI 35% to 59%). We would need to treat
4 people (95% CI 4 to 6 people) with oral cryotherapy in order to
prevent one additional person from developing moderate to severe
oral mucositis.
High-dose melphalan-based treatment prior to stem cell
transplantation
The same five studies (Askarifar 2015; Lilleby 2006; Salvador 2012;
Svanberg 2007; Toro 2013), when combined, showed that there
is evidence to show that oral cryotherapy reduced the risk of
developing moderate to severe oral mucositis (RR 0.43, 95% CI 0.17
to 1.09, P = 0.07) when compared to control (Analysis 1.2). Oral
cryotherapy reduced the risk of developing moderate to severe
oral mucositis by 57% although the uncertainty surrounding this
eEect estimate means that the 95% CI ranges from a 83% reduction
to a 9% increase in risk. We would need to treat 3 people with
oral cryotherapy to prevent one additional person from developing
moderate to severe oral mucositis. The confidence interval ranges
from 2 people needing to receive oral cryotherapy to prevent
one additional person from developing moderate to severe oral
mucositis, to 17 people needing to receive oral cryotherapy for one
additional person to develop moderate to severe oral mucositis.
There was considerable heterogeneity associated with this eEect
estimate (I2 = 92%), although the reason/s for this inconsistency is/
are not clear on investigation of the characteristics of the studies,
in terms of the participants, settings, methods, and interventions.
Methotrexate treatment post-stem cell transplantation to prevent
graJ versus host disease
The same study (Gori 2007) showed that there is insuEicient
evidence to determine whether or not oral cryotherapy reduces the
risk of developing moderate to severe oral mucositis (RR 1.01, 95%
CI 0.85 to 1.20, P = 0.93) when compared to control (Analysis 1.2).
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Oral mucositis (severe)
Fluorouracil (5FU) treatment for solid cancers
The same five studies (Cascinu 1994; Heydari 2012; Katranci 2012;
Mahood 1991; Sorensen 2008), when combined, showed that oral
cryotherapy reduced the risk of developing severe oral mucositis
(RR 0.40, 95% CI 0.27 to 0.61, P < 0.0001) when compared to
control (Analysis 1.3). There was no heterogeneity (I2 = 0%). Oral
cryotherapy reduced the risk of developing severe oral mucositis by
60% (39% to 73%). We would need to treat 6 people (95% CI 5 to
9 people) with oral cryotherapy to prevent one additional person
from developing severe oral mucositis.
High-dose melphalan-based treatment prior to stem cell
transplantation
The same five studies (Askarifar 2015; Lilleby 2006; Salvador 2012;
Svanberg 2007; Toro 2013), when combined, showed that oral
cryotherapy reduced the risk of developing severe oral mucositis
(RR 0.38, 95% CI 0.20 to 0.72, P = 0.003) when compared
to control (Analysis 1.3). Oral cryotherapy reduced the risk of
developing severe oral mucositis by 62% (95% CI 28% to 80%).
We would need to treat 4 people (95% CI 3 to 9 people)
with oral cryotherapy to prevent one additional person from
developing severe oral mucositis. There was moderate amount
of heterogeneity associated with this eEect estimate (I2 = 42%),
although the reason/s for this inconsistency is/are not clear on
investigation of the characteristics of the studies, in terms of the
participants, settings, methods, and interventions.
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Methotrexate treatment post-stem cell transplantation to prevent
graJ versus host disease
The same study (Gori 2007) showed that there is insuEicient
evidence to determine whether or not oral cryotherapy reduces the
risk of developing moderate to severe oral mucositis (RR 0.88, 95%
CI 0.61 to 1.25, P = 0.47) when compared to control (Analysis 1.3).
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Interruptions to cancer treatment
Fluorouracil (5FU) treatment for solid cancers
One study (Heydari 2012), at high risk of bias and analysing 80
participants, showed that oral cryotherapy reduced the risk of
treatment interruption (RR 0.44, 95% CI 0.20 to 0.95, P = 0.04) when
compared to control (Analysis 1.4). In other words, oral cryotherapy
reduced the risk of treatment interruption by 56% (95% CI 5% to
80%). We would need to treat 5 people (95% 4 to 50 people) with
oral cryotherapy in order to prevent one additional person from
having a treatment interruption. The uncertainty, due to the single
study with a small number of participants, surrounding this eEect
estimate is reflected by the wide range in the confidence interval.
The same study showed that oral cryotherapy reduced the duration
of treatment interruption by eight days (95% CI 9.26 to 6.74 days, P
< 0.00001) when compared to control (Analysis 1.5).
High-dose melphalan-based treatment prior to stem cell
transplantation
No studies in this subgroup assessed this outcome.
GraJ versus host disease prophylaxis
The study in this subgroup did not assess this outcome.
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Oral pain
Fluorouracil (5FU) treatment for solid cancers
One study (Heydari 2012), at high risk of bias and analysing 80
participants, showed that oral cryotherapy reduced the duration of
oral pain experience (MD -1.93, 95% CI -2.37 to -1.49, P < 0.00001)
when compared to control (Additional Table 1). The 1 to 5 scale
used to measure this outcome makes it impossible to accurately
interpret this result in any meaningful way.
High-dose melphalan-based treatment prior to stem cell
transplantation
Two studies (Lilleby 2006; Salvador 2012), both at high risk of
bias and analysing 85 participants, showed that oral cryotherapy
reduced the intensity of oral pain (MD -1.50, 95% CI -2.11 to -0.89,
P < 0.00001) when compared to control (Analysis 1.6). There was
a negligible amount of heterogeneity associated with this eEect
estimate (I2 = 4%). This result represents a 70% reduction in oral
pain but this figure may be misleading as there was only a 1.5 point
reduction on a 0 to 10 scale.
GraJ versus host disease prophylaxis
The study in this subgroup did not assess this outcome.
Radiotherapy to the head and neck
The study in this subgroup assessed oral pain but did not report
details of the scale used, so we were unable to use the data.
Quality of life
Fluorouracil (5FU) treatment for solid cancers
No studies in this subgroup assessed this outcome.
High-dose melphalan-based treatment prior to stem cell
transplantation
One study assessed this outcome but the data are currently
unavailable as the study report and analysis have not yet been
completed (Toro 2013).
GraJ versus host disease prophylaxis
The study in this subgroup did not assess this outcome.
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Normalcy of diet
Fluorouracil (5FU) treatment for solid cancers
No studies in this subgroup assessed this outcome.
High-dose melphalan-based treatment prior to stem cell
transplantation
One study, at high risk of bias and analysing 78 participants
(Svanberg 2007), showed that oral cryotherapy reduced the
duration of total parenteral nutrition by 2.18 days (95% CI 0.03 to
4.33 days, P = 0.05) when compared to control (Analysis 1.7).
A further study, at high risk of bias and analysing 40 participants
(Lilleby 2006), reported that oral cryotherapy reduced the number
of days of total parenteral nutrition (Additional Table 1).
GraJ versus host disease prophylaxis
The study in this subgroup did not assess this outcome.
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Adverse events
Fluorouracil (5FU) treatment for solid cancers
One study reported that there were no adverse eEects ("problems")
(Katranci 2012), whilst the other four studies reported low rates
of very minor adverse events (headache, chills, numbness/taste
disturbance).
High-dose melphalan-based treatment prior to stem cell
transplantation
One study did not report adverse events (Askarifar 2015), whilst
another informed us by email that there were "no serious adverse
events" (Toro 2013). The remaining two studies reported only
low rates of shooting pain from the teeth (Svanberg 2007), and
coldness (Lilleby 2006). In the latter study, this stopped some
participants from continuing the cryotherapy regimen, although
this is not surprising as they were required to hold ice in their
mouths continuously for a total of seven hours.
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GraJ versus host disease prophylaxis
The study in this subgroup did not report on adverse events.
Radiotherapy to the head and neck
The study in this subgroup did not report on adverse events.
However, we assume that there were none because the participants
only had to hold ice in their mouth for 5-minute periods.
Number of days in hospital
Fluorouracil (5FU) treatment for solid cancers
No studies in this subgroup assessed this outcome.
High-dose melphalan-based treatment prior to stem cell
transplantation
Two studies (Salvador 2012; Svanberg 2007), both at high risk of
bias and analysing 123 participants, were combined in a meta-
analysis with no heterogeneity (I2 = 0%). There is insuEicient
evidence to show that oral cryotherapy reduces the duration of
hospitalisation (MD -1.39 days, 95% CI -2.97 to 0.19 days, P = 0.09)
when compared to control (Analysis 1.8).
A further study, at high risk of bias and analysing 40 participants
(Lilleby 2006), reported that there was insuEicient evidence to show
a reduction in the duration of hospitalisation (Additional Table 1).
GraJ versus host disease prophylaxis
The study in this subgroup did not assess this outcome.
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Number of days of treatment with opioid analgesics
Fluorouracil (5FU) treatment for solid cancers
No studies in this subgroup assessed this outcome.
High-dose melphalan-based treatment prior to stem cell
transplantation
One study (Svanberg 2007), at high risk of bias and analysing
78 participants, showed that there is insuEicient evidence to
determine whether or not oral cryotherapy reduces the duration of
opioid use (MD -2.28 days, 95% CI -5.33 to 0.77 days, P = 0.14) when
compared to control (Analysis 1.9).
A further study (Lilleby 2006), at high risk of bias and analysing 40
participants, reported that oral cryotherapy reduced the duration
of opioid use (Additional Table 1).
GraJ versus host disease prophylaxis
The study in this subgroup did not assess this outcome.
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Number of days unable to take medicine orally
Fluorouracil (5FU) treatment for solid cancers
No studies in this subgroup assessed this outcome.
High-dose melphalan-based treatment prior to stem cell
transplantation
No studies in this subgroup assessed this outcome.
GraJ versus host disease prophylaxis
The study in this subgroup did not assess this outcome.
Radiotherapy to the head and neck
The study in this subgroup did not assess this outcome.
Comparison 2: Di=erent oral cryotherapy regimens
One study (Rocke 1993), at high risk of bias and analysing 178
participants having treatment for solid cancer (fluorouracil and
leucovorin), showed that there is insuEicient evidence to determine
whether or not the risk of developing oral mucositis is diEerent
when using 30 minutes or 60 minutes of oral cryotherapy (RR 0.89,
95% CI 0.62 to 1.29, P = 0.54) (Analysis 2.1).
The results were similar for the risk of developing moderate to
severe oral mucositis (RR 0.68, 95% CI 0.36 to 1.30, P = 0.25)
(Analysis 2.2), and severe oral mucositis (RR 0.60, 95% CI 0.23 to
1.58, P = 0.30) (Analysis 2.3).
The study in this comparison did not assess any other outcomes of
this review.
Comparison 3: Cryotherapy versus chlorhexidine
One study (Sorensen 2008), at high risk of bias and analysing 133
participants having treatment for solid cancer (fluorouracil and
leucovorin), showed that there is insuEicient evidence to determine
whether or not the risk of developing oral mucositis is diEerent
when using oral cryotherapy or chlorhexidine rinse (RR 0.97, 95% CI
0.71 to 1.32, P = 0.84) (Analysis 3.1).
The results were similar for the risk of developing moderate to
severe oral mucositis (RR 0.89, 95% CI 0.51 to 1.56, P = 0.68)
(Analysis 3.2), and severe oral mucositis (RR 0.86, 95% CI 0.34 to
2.18, P = 0.76) (Analysis 3.3).
The study in this comparison did not assess any other outcomes of
this review.
Comparison 4: Cryotherapy versus low-dose leucovorin versus
high-dose leucovorin
One study (Zhang 2011), at high risk of bias and analysing 147
participants having treatment for solid (osteosarcoma) cancer
(high-dose methotrexate, vincristine and leucovorin), showed that
oral cryotherapy reduced the risk of developing oral mucositis
when compared to both low-dose leucovorin rinse (RR 0.67, 95% CI
0.50 to 0.90, P = 0.008) and high-dose leucovorin rinse (RR 0.65, 95%
CI 0.47 to 0.90, P = 0.01) (Analysis 4.1).
There was insuEicient evidence to determine whether or not the
risk of developing moderate to severe oral mucositis is diEerent
when using oral cryotherapy or low-dose leucovorin rinse (RR 0.18,
95% CI 0.01 to 3.42, P = 0.25), or when using oral cryotherapy
compared to high-dose leucovorin rinse (not estimable - no
participants had developed moderate or severe oral mucositis by
the fourth day aNer chemotherapy when the data were reported)
(Analysis 4.2).
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There was insuEicient evidence to determine whether or not the
risk of developing severe oral mucositis is diEerent when using oral
cryotherapy compared to either low-dose or high-dose leucovorin
rinse (Analysis 4.3). No participants had developed severe oral
mucositis by the fourth day aNer chemotherapy when the data were
reported.
The study in this comparison did not assess any other outcomes of
this review.
Compliance
Two studies did not report on compliance (Askarifar 2015; Zhang
2011). The remaining studies reported a high degree of compliance,
with the large majority of participants managing to keep their
mouths constantly cooled.
D I S C U S S I O N
Summary of main results
Fourteen randomised controlled trials (RCTs) met our eligibility
criteria and were included in this review. We assessed the body
of evidence for each comparison and outcome using GRADE
methodology (GRADE 2004). Most of the evidence we found relates
to the comparison of oral cryotherapy versus a control group of
standard care or no treatment in adult patients. We only present a
'Summary of findings' table where we were able to perform a meta-
analysis for the main outcomes, thus we produced two separate
tables for: 1) evidence for participants receiving fluorouracil-based
(5FU) treatment for solid cancers (Summary of findings for the main
comparison); and 2) evidence for participants receiving high-dose
melphalan-based cancer treatment prior to haematopoietic stem
cell transplantation (HSCT) (Summary of findings 2).
Our main findings are as follows.
Adults receiving 5FU-based treatment for solid cancers
• Oral cryotherapy probably reduces oral mucositis of all
severities (moderate quality evidence).
• There is some weak evidence that oral cryotherapy reduces both
the incidence of treatment interruptions and the duration of
treatment interruptions (very low quality evidence).
• There is some weak evidence that oral cryotherapy reduces the
duration of pain experience (very low quality evidence).
Adults receiving high-dose melphalan prior to HSCT
• Oral cryotherapy may reduce the incidence of both oral
mucositis (any severity versus none) and moderate to severe
oral mucositis (low quality evidence), and probably does
reduce the incidence of severe oral mucositis (moderate quality
evidence).
• Oral cryotherapy may lead to a small reduction in oral pain (low
quality evidence).
• There is some weak evidence that oral cryotherapy reduces the
duration of total parenteral nutrition (TPN) (very low quality
evidence).
• There is insuEicient evidence to determine whether or not oral
cryotherapy reduces the number of days in hospital (low quality
evidence).
• There is insuEicient evidence to determine whether or not oral
cryotherapy reduces the number of days of treatment with
opioid analgesics (very low quality evidence).
There is insuEicient evidence to determine the eEects of oral
cryotherapy in: a) people receiving low-dose methotrexate for
preventing graN-versus-host disease (GVHD) aNer HSCT; and b)
people receiving head and neck radiotherapy (both very low quality
evidence).
For the other comparisons included in this review, there was
only very low quality evidence provided by single studies. In
participants receiving 5FU-based treatment for solid cancers, there
is insuEicient evidence to determine whether or not there is
a diEerence between: a) 30 minutes and 60 minutes of oral
cryotherapy; or b) oral cryotherapy and chlorhexidine rinse, for
reducing the risk of developing any severity of oral mucositis.
In participants receiving high-dose methotrexate, vincristine and
leucovorin for bone cancer (osteosarcoma), there is some weak
evidence that oral cryotherapy reduces the risk of developing oral
mucositis when compared to leucovorin rinses.
Oral cryotherapy is safe, with low rates of very minor adverse
eEects, which ensures that compliance with this therapy is
generally high.
Overall completeness and applicability of evidence
We have found evidence which partially answers the review
question of whether or not oral cryotherapy can prevent oral
mucositis in cancer patients who are receiving treatment. We
have enough evidence to answer this question for adults
receiving 5FU-based treatment for solid cancers in a satisfactory
manner. However, for adults with haematological cancers receiving
melphalan-based cancer treatment prior to HSCT, the evidence is
not complete and may be diEicult to apply to diEerent settings
due to conflicting results amongst the individual studies. We would
welcome more evidence in this group of patients and in a variety
of settings. There is also very limited evidence on people receiving
chemotherapy as GVHD prophylaxis, and also people receiving
radiotherapy, whilst there is no RCT evidence on people receiving
targeted therapy. The rationale behind the biological plausibility for
using oral cryotherapy in cancer patients receiving chemotherapy
has been explained in the literature. However, this is not the case
for patients receiving radiotherapy to the head and neck or targeted
therapy, which makes it diEicult to determine the procedure (i.e.
when and for how long to perform cryotherapy), yet it is still
worth further investigation if there is a chance that this simple
intervention can help these patients.
There is no evidence on the eEects of this intervention in children,
perhaps because it may be considered unfeasible to expect children
to hold ice in their mouths for long periods of time, due to the
discomfort caused. However, as demonstrated in some of the
studies included in this review, there are alternatives to holding
crushed ice or ice chips or ice cubes in the mouth, such as the use
of iced water/drinks or ice lollies/popsicles. It is also possible that
ice chips or cubes may be a potential choking hazard in children.
There is also a lack of evidence on the eEects of oral cryotherapy in
low-income and lower-middle-income countries.
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Quality of the evidence
We included 14 RCTs that analysed 1280 participants. The body
of evidence that we identified on adults receiving 5FU-based
treatment for solid cancers allows a fairly robust conclusion to
be made about the eEects of oral cryotherapy for reducing the
risk of oral mucositis in that group of patients. That is to say we
can be quite confident in the results and we therefore assessed
the evidence as being of moderate quality. We downgraded the
rating of the evidence by one level due to the lack of blinding of
participants, personnel and outcome assessors. Lack of blinding
of participants and personnel in these studies is an unavoidable
problem and does not necessarily reflect the 'quality' in terms of
whether or not the studies were well conducted, although it does
aEect the risk of bias, which we must account for in our assessment
of the quality of the body of evidence. Future studies may avoid the
risk of detection bias by using a more objective measurement tool
for the assessment of oral mucositis. However, this would aEect
our ability to combine the new studies in meta-analyses with the
current published studies that all use either the WHO or NCI-CTC
tools, which incorporate subjective elements.
The body of evidence that we identified on adults receiving high-
dose melphalan-based cancer treatment prior to HSCT does not
allow for such robust conclusions for the outcomes 'any mucositis'
and 'moderate to severe mucositis'. There were the same problems
with risk of bias as discussed above, and also inconsistency in the
results of the individual studies, and we therefore downgraded
our rating of the quality of the body of evidence by two levels,
resulting in low quality evidence. Although we would conclude that
oral cryotherapy may be beneficial in this group of patients, the
results were very uncertain, with wide confidence intervals, and
even the possibility of a slight increase in the risk of developing any
or moderate to severe mucositis. However, we did not downgrade
for precision as the upper confidence limits did not include
appreciable harm, and also because we do not consider it to be very
low quality evidence. The evidence for oral cryotherapy reducing
the risk of severe oral mucositis in this group of patients was more
robust, resulting in moderate quality evidence.
We did not downgrade either of the above bodies of evidence
for indirectness resulting from the studies only being conducted
on adults. However, there is some evidence that, with some
diseases, children have more toxicity than adults who receive the
same chemotherapy regimens (Juergens 2006). Therefore, it is
possible that results in adults are not directly applicable to children,
who may metabolise drugs diEerently and therefore experience
diEerent toxicity severity.
There was insuEicient evidence, of very low quality, on the eEects
of oral cryotherapy for reducing the risk of oral mucositis to allow
any conclusions to be made for people receiving chemotherapy as
GVHD prophylaxis, and also people receiving radiotherapy. This was
downgraded for risk of bias, imprecision and indirectness, the latter
because they were single study subgroups and were not replicated
in any other settings. There was no evidence relating to children-
only.
It was unfortunate that there was such limited evidence on the
secondary outcomes of this review. These outcomes, and others,
are likely to be important to patients and clinicians, and this serves
to highlight the importance of core outcomes sets such as the
one published by Bellm et al (Bellm 2002). We would urge future
trialists to utilise such outcome sets in order to standardise what is
measured and how it is measured, so as to maximise the usefulness
of data produced by the randomisation of people, and thus reduce
research waste.
Potential biases in the review process
We attempted to minimise biases in the review process but we
cannot discount the fact that it is aEected by other biases. For
example, there were two studies that presented oral mucositis
incidence data on multiple days rather than our preferred format
of presenting a maximum score experienced per participant over
the whole study period (Askarifar 2015; Katranci 2012). Rather than
lose important data, we decided to present the data from the day
on which the incidence of grades higher than 0 was highest. We
chose this method with the intention of equating to the maximum
score experience, though we acknowledge this is not ideal and may
not equate accurately enough. Another decision we made was to
exclude studies where the participants received oral cryotherapy
plus another intervention, even if the control group also received
the other intervention. For example, one study that we excluded
compared oral cryotherapy plus laser therapy versus laser therapy
(de Paula Eduardo 2014). We could not exclude the possibility of
interaction between the interventions and therefore we would not
be confident in stating that any eEect was due to the cryotherapy.
However, in some of the studies, both groups received standard
care, with the intervention group also receiving oral cryotherapy.
We felt that this was a diEerent situation because the standard
care involved things like advice and education on mouth care, or
mouth rinsing with saline, none of which would interact with the
cryotherapy in a way that could bias the results.
Agreements and disagreements with other studies or
reviews
A recent meta-analysis conducted in China on oral cryotherapy for
preventing oral mucositis in patients with haematological cancers
undergoing HSCT (Wang 2015), concluded that oral cryotherapy
reduces the incidence of severe oral mucositis (risk ratio (RR)
0.52, 95% confidence interval 0.27 to 0.99). This was a smaller
reduction than we calculated (RR 0.38, 95% CI 0.20 to 0.72), but
they included one study that we excluded due to the possibility
of confounding (de Paula Eduardo 2014), another study that we
did not include in this subgroup due to treatment diEerences (Gori
2007), and another study that we have been unable to obtain
the data for, which is currently listed in Characteristics of studies
awaiting classification (Lu 2013). We included two studies that the
Chinese authors did not include, for which we managed to obtain
data through correspondence with the study authors (Askarifar
2015; Salvador 2012). The Chinese authors were also in agreement
with our results on 'duration of opioid use' and 'days of TPN',
although they included data from Lilleby 2006, which reported
medians and ranges for some of our outcomes, and it was not clear
what methods they used to include this study in the meta-analyses.
The inclusion of Lilleby 2006 data in their meta-analysis for the
outcome 'duration of hospitalisation' resulted in a significant result
in favour of oral cryotherapy, in contrast to our result which did not
achieve significance.
Our results strongly support the conclusions of another systematic
review of oral cryotherapy that was carried out by the Mucositis
Study Group (MSG) of the Multinational Association of Supportive
Care in Cancer/International Society of Oral Oncology (MASCC/
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ISOO), and that is not limited to RCTs (Peterson 2013). This review
feeds into the 'MASCC/ISOO Clinical Practice Guidelines for the
Management of Mucositis Secondary to Cancer Therapy (Lalla
2014). Specifically, the guidance from this group is currently as
follows.
• Recommendations in favour of an intervention (i.e. strong
evidence supporting eEectiveness): The panel recommends that
30 minutes of oral cryotherapy be used to prevent oral mucositis
in patients receiving bolus 5FU chemotherapy (level II evidence).
• Suggestions in favour of an intervention (i.e. weaker evidence
supporting eEectiveness): The panel suggests that oral
cryotherapy be used to prevent oral mucositis in patients
receiving high-dose melphalan, with or without total body
irradiation, as conditioning for HSCT (level III evidence).
This guidance is perhaps further strengthened by our Cochrane
systematic review, as we have included new data/evidence
not included in the MASCC/ISOO review or guidelines, yet the
conclusions remain the same. It could even be argued that,
due to the new data included in our two subgroups of patients
matching those above, the level of evidence would now be level
I for patients receiving bolus 5FU chemotherapy, and level I or II
for patients receiving high-dose melphalan, with or without total
body irradiation, as conditioning for HSCT. Level I evidence is
"evidence obtained from meta-analysis of multiple, well-designed,
controlled studies; randomized trials with low false-positive and
false-negative errors (high power)" (Lalla 2014). There are now five
RCTs in our 5FU subgroup with suEicient power to give a clear
and fairly precise result. Our melphalan subgroup also now has
five RCTs, but with fewer participants, giving a less precise result.
However, the evidence for prevention of severe oral mucositis in
this subgroup is fairly robust.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We are confident that oral cryotherapy leads to large reductions in
the incidence of oral mucositis of all severities in adults receiving
fluorouracil-based (5FU) treatment for solid cancers. We are less
confident in the ability of oral cryotherapy to reduce the incidence
of oral mucositis in adults receiving high-dose melphalan-based
cancer treatment prior to haematopoietic stem cell transplantation
(HSCT). Evidence suggests that it does reduce oral mucositis in
these adults, but we are less certain about the size of the reduction,
which could be large or small. However, we are confident that there
is an appreciable reduction in severe oral mucositis in these adults.
This Cochrane systematic review has included some very recent
and currently unpublished data, and strengthens international
guideline statements for adults receiving the above cancer
treatments.
Implications for research
It is fairly clear that oral cryotherapy is beneficial for adults
receiving 5FU chemotherapy, and therefore further randomised
controlled trials (RCTs) are probably not warranted. Instead, it
may be better to conduct new head-to-head RCTs comparing oral
cryotherapy with other promising preventive treatments such as
lasers, growth factors and cytokines, and other interventions.
We need more studies assessing oral cryotherapy in people
receiving high-dose melphalan-based cancer treatment prior to
HSCT in order to further strengthen the body of evidence reported
in this review. Further investigation of the optimum cryotherapy
regimen may be warranted in these patients and, as mentioned
above, more head-to-head studies. We also need more studies
looking at the eEects of oral cryotherapy in people receiving
other cancer treatments, such as diEerent chemotherapy drugs
(including those given as prophylaxis for graN-versus-host disease
aNer HSCT), radiotherapy, and even targeted therapies. Studies
of children may also be warranted if this intervention can help
them complete their optimum cancer treatment regimens, whilst
minimising their pain, discomfort and ability to eat and drink
properly.
We urge trialists conducting future RCTs to measure and report
all the outcomes, as a minimum, listed in the core outcome set
produced by Bellm et al (Bellm 2002). For our primary outcome of
oral mucositis, it would be beneficial to use both a measurement
tool such as the WHO or NCI-NCT scale (Appendix 8), to allow us to
combine the data with those already included in this review, and
also an objective scale with blinded outcome assessment, in order
to reduce the bias inherent in these studies.
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Characteristics of included studies [ordered by study ID]
 
Methods Trial design: parallel (2 arms)
Location: Iran
Number of centres: 1
Study duration: April to September 2013
Askarifar 2015 
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Participants Inclusion criteria: full consciousness; suffering Hodgkin or non-Hodgkin lymphoma or multiple myelo-
ma; good oral health; isolation in a separate room; undergoing similar basic chemotherapy; undergo-
ing first course of chemotherapy; undergoing autologous BMT
Exclusion criteria: patient dissatisfaction; loss of consciousness; susceptible to other diseases that
could potentially disrupt treatment; use of analgesics continuously prior to start of study; receiving
combined therapies such as radiotherapy; fever; neutropenia; mucositis prior to the treatment; respi-
ratory diseases; oral infections; systemic diseases affecting oral health (especially periodontal tissues);
more than 2 weeks interval between chemotherapy and transplantation; changes in treatment proto-
col during the study
Cancer type: haematological (Hodgkin: Gp A: 31%; Gp B: 46%; non-Hodgkin: Gp A: 13%; Gp B: 23%;
multiple myeloma: Gp A: 56%; Gp B: 31%)
Cancer treatment: melphalan for Hodgkin and non-Hodgkin lymphoma; melphalan, cytarabine,
etoposide, and lomustine for multiple myeloma ("There were no differences in terms of...treatment
regimen")
Any other potentially important prognostic factors: "There were no differences in terms of...educa-
tional status"; smokers: Gp A: 13%; Gp B: 31%
Age at baseline (years): Gp A: 43 (range 19 to 66); Gp B: 39.8 (range 21 to 62)
Gender: Gp A: 56% male; Gp B: 62% male
Number randomised: 33 (Gp A: 17; Gp B: 16)
Number evaluated: 29 (Gp A: 16; Gp B: 13)
Interventions Comparison: cryotherapy versus normal saline
Gp A: prior to BMT, ice cubes held in mouth 5 min before start of chemotherapy, held for 30-min periods
with maximum 20-min breaks between each period, until 5 min after completion of chemotherapy
Gp B: prior to BMT, 30 to 50 cc of saline mouthwash used 30 min before start of chemotherapy, then
again every half-hour, until 6 hours after completion of chemotherapy
Compliance: not reported
Duration of treatment (intended): not reported but probably variable depending on chemotherapy
regimen
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed on days 3, 7, 14 and 21 and reported as a mean on each
separate assessment day); we requested maximum score experienced per participant over the whole
study period but the authors provided incidence of each grade on days 3, 7 and 14
• Neutrophil rate (not an outcome of this review)
Notes Sample size calculation: based on detection of MD of 0.51, with 80% power at 5% significance level,
and accounting for 40% attrition (14 per group required)
Adverse effects: not reported
Funding: "financial support of Tabriz University of Medical Sciences"
Declarations/conflicts of interest: "Authors declare no conflict of interest in this study"
Data handling by review authors: the authors provided us with data on the incidence of each oral mu-
cositis grade on days 3, 7 and 14, and we used the data for day 7 in our meta-analyses as the incidence
of grades > 0 was highest and therefore probably most closely equates to the maximum score experi-
enced per participant (as reported in the other studies in the meta-analyses)
Askarifar 2015  (Continued)
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Other information of note: the information on this study is obtained from a pre-publication copy of
the study report provided to us by the authors, and also from correspondence with the authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The patients randomly were allocated into control and intervention
groups using size-2 random blocks and based on a 1:1 allocation ratio random
numbers were generated by "Random software Allocation" software"
Comment: computer generated randomisation so probably done adequately
Allocation concealment
(selection bias)
Low risk Quote: "The patients randomly were allocated into control and intervention
groups using size-2 random blocks and based on a 1:1 allocation ratio random
numbers were generated by "Random software Allocation" software"
Correspondence: "the allocation was performed by a person who was not in-
volved in sampling and analysis"
Comment: appears to be third-party randomisation which should have en-
sured that the allocation sequence was not manipulated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 12% of randomised participants were not included in the analyses (Gp A: 6%;
Gp B: 19%). All drop-outs were due to fever but this could be a risk of bias if the
fever was linked to oral mucositis
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Askarifar 2015  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Pesaro, Italy
Number of centres: 1
Study duration: not reported
Participants Inclusion criteria: first ever course of chemotherapy
Exclusion criteria: not reported
Cancer type: Gp A: 98% gastrointestinal, 2% prostrate; Gp B: 98% gastrointestinal, 2% prostrate
Cancer treatment: 5FU, different dosages and co-treatments (LV, IFN, VP16) equally distributed be-
tween groups due to stratification
Cascinu 1994 
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Any other potentially important prognostic factors: performance status (EOCG): Gp A: 0 = 50%, 1 =
32%, 2 = 18%; Gp B: 0 = 50%, 1 = 35%, 2 = 15%; denture wearers equally distributed between groups
due to stratification
Age at baseline (years): Gp A: median 60 (range 38 to 73); Gp B: median 58 (range 44 to 72)
Gender: Gp A: 68% male; Gp B: 70% male
Number randomised: 84 (Gp A: 44; Gp B: 40)
Number evaluated: 84 (Gp A: 44; Gp B: 40)
Interventions Comparison: cryotherapy versus no treatment
Gp A: ice chips placed in mouth 5 min before 5FU and continuously swished around, then replenished
before the previous ice had completely melted, for total 30 min
Gp B: 5FU only
All participants were asked to remove dentures
Compliance: all Gp A participants received cryotherapy in the first cycle but 2 participants "noted an
'ice cream' headache which caused them to refuse this technique after the second and third cycle of
chemotherapy, respectively"
Duration of treatment (intended): not reported (variable and dependent on number of cycles of can-
cer treatment)
Outcomes • Oral mucositis: global assessment of the physician's judgement and participants' description on a 0 to
4 scale (very similar to WHO scale and NCI common toxicity criteria) based on methods of Mahood 1991
(assessed after each cycle and reported as first cycle only and all cycles, maximum score reported)
• Duration of oral mucositis (not an outcome of this review)
• Other adverse effects of cancer treatment (not an outcome of this review)
Notes Sample size calculation: not reported
Adverse effects: 2 participants in the cryotherapy group "noted an 'ice cream' headache"
Funding: not reported
Declarations/conflicts of interest: not reported
Data handling by review authors: data reported as all cycles (so double-counting is a problem) and
first cycle only, so we used the data for first cycle only
Other information of note: mean oral mucositis score reported by smoking status for each group for
the first cycle only (smokers had higher mean oral mucositis score than non-smokers in both groups)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomised to a control arm or to receive cryotherapy"
Correspondence: "Randomisation using cards from a computer generated list
in sealed envelopes was performed by a person not involved with the care or
evaluation of the patient"
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: "randomised to a control arm or to receive cryotherapy"
Cascinu 1994  (Continued)
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Correspondence: "Randomisation using cards from a computer generated list
in sealed envelopes was performed by a person not involved with the care or
evaluation of the patient"
Comment: third-party randomisation and use of sealed envelopes should have
ensured that the allocation sequence was not manipulated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately. Although only
the oral mucositis outcome was mentioned in the methods, this is more like-
ly to be related to reporting quality rather than bias as the study pre-dates the
CONSORT statement (CONSORT 2010)
Other bias Low risk No other sources of bias are apparent
Cascinu 1994  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: various locations in Italy
Number of centres: "multicentre" but unclear how many centres; co-ordinated by the Institute of
Hematology and Medical Oncology, University of Bologna
Study duration: October 2004 to January 2006
Participants Inclusion criteria: undergoing allogeneic HSCT and MTX-containing GVHD prophylaxis; minimum age 8
years
Exclusion criteria: clinical evidence of oral mucositis; participants not receiving at least 3 administra-
tions of MTX following HSCT
Cancer type: haematological (types were equally distributed between groups)
Cancer treatment: pre-transplant radio/chemotherapy generally comparable between groups; total
body irradiation: Gp A: 30.6%; Gp B: 28.3%
Any other potentially important prognostic factors: stem cell donor related: Gp A: 45.1%; Gp B:
58.3%; stem cell source: Gp A: marrow = 33.9%, peripheral blood = 66.1%; Gp B: marrow = 28.3%, pe-
ripheral blood = 71.7%; folinic acid rescue: Gp A: 43.5%; Gp B: 38.3%
Age at baseline (years): Gp A: median 35.5 (range 9 to 59); Gp B: median 40 (range 8 to 66)
Gender: Gp A: 51.6% male; Gp B: 50% male
Number randomised: 130 (not reported by group)
Gori 2007 
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Number evaluated: 122 (Gp A: 62; Gp B: 60)
Interventions Comparison: cryotherapy versus no treatment
Gp A: after allogeneic HSCT, ice chips (mineral water) or popsicles placed in mouth for minimum 60 min
starting from the time of low-dose MTX administration (20 mg/m2 on day +1, 15 mg/m2 on days +3, +6
and +11) as an IV infusion lasting 5 min (± 2), and replenished when melted
Gp B: after allogeneic HSCT, MTX as above
Compliance: "Six patients enrolled in the cryotherapy arm did not actually complete cryotherapy as
planned because of refusal or poor tolerance. However, the exclusion of these patients did not change
the results"
Duration of treatment (intended): 4 occasions (minimum of 60 min) on 4 separate days (days 1, 3, 6
and 11)
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed once daily for 20 to 30 days, maximum score reported)
• Duration of moderate to severe (grade 2 to 4) and severe (grade 3 to 4) oral mucositis (not an outcome
of this review)
Notes Sample size calculation: based on previous study, 90% power at 5% significance (unclear whether re-
quired sample size was achieved)
Adverse effects: not reported, only refers to the 6 participants who did not complete cryotherapy due
to "refusal or poor tolerance"
Funding: "We thank the Italian HSCT Nurses Group (GITMO) for sponsoring the study"
Declarations/conflicts of interest: not reported
Data handling by review authors: data is maximum oral mucositis score across all cycles of MTX
Other information of note: univariate and multivariate analyses showed severe (grade 3 to 4) oral mu-
cositis was significantly associated with total body irradiation and lack of folinic acid rescue
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "After giving their informed consent, patients were included in a pre-
formed randomization list that was updated by the coordinating center. Ran-
domization was performed at the ratio of 1 patient per arm with no further
stratifications"
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Unclear risk Quote: "After giving their informed consent, patients were included in a pre-
formed randomization list that was updated by the coordinating center. Ran-
domization was performed at the ratio of 1 patient per arm with no further
stratifications"
Comment: co-ordinating centre mentioned, but unclear whether or not they
allocated participants remotely from this centre (central randomisation by a
third party)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Gori 2007  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 6% of the participants were not included in the analyses but this attrition was
not reported by group. However, the amount of attrition was low and reasons
are fully reported
Selective reporting (re-
porting bias)
Low risk Data for the primary outcome of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Gori 2007  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Mashhad, Iran
Number of centres: 2
Study duration: March 2007 to April 2008
Participants Inclusion criteria: able to undergo one of the chemotherapy regimens described in the study at a stan-
dard dose; normal laboratory levels (including complete blood counts); normal kidney and hepatic
function; participant or carer able to read and write
Exclusion criteria: previous chemotherapy; not undergoing one of the combined courses of
chemotherapy described in the study; treated with head and neck radiotherapy; diabetic
Cancer type: Gp A: 55% colorectal, 45% breast; Gp B: 45% colorectal, 55% breast
Cancer treatment:
• MAYO (mean infusion time 20 min): 5FU (425 mg/m2) and LV (25 mg/m2) for 5 days, repeated every 28
days: Gp A: 55%; Gp B: 45%
• CAF (mean infusion time 25 to 35 min): cyclophosphamide (500 mg/m2), adriamycin (50 mg/m2) and
5FU (500 mg/m2) on 1st day of cycle, repeated every 21 days: Gp A: 30%; Gp B: 42.5%
• CMF (mean infusion time 25 to 35 min): cyclophosphamide (600 mg/m2), MTX (40 mg/m2) and 5FU
(600 mg/m2) on 1st day of cycle, repeated every 28 days: Gp A: 15%; Gp B: 12.5%
Any other potentially important prognostic factors: no statistically significant differences between
groups in the following factors: tooth status, smoking status, mouthwash use, brushing habit, BMI, ed-
ucational status
Age at baseline (years): Gp A: mean 59.5 (SD 12.35); Gp B: mean 63.25 (SD 15.06)
Gender: 40% male overall and reports that there were no statistically significant differences between
groups
Number randomised: 80 (Gp A: 40; Gp B: 40)
Number evaluated: 80 (Gp A: 40; Gp B: 40)
Interventions Comparison: cryotherapy versus no treatment
Gp A: ice chips placed in mouth 5 min before chemotherapy until 5 min after and continuously swished
around, then replenished before the previous ice had completely melted
Heydari 2012 
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Gp B: chemotherapy only
All participants were asked to remove dentures
Compliance: well tolerated, no discontinuation of therapy, and most participants kept their mouths
constantly cool for most of the chemotherapy session
Duration of treatment (intended): mean duration of cryotherapy was 20 to 45 min for a session; those
receiving MAYO regimen (see above) had cryotherapy for each of the 5 days of treatment, whilst those
receiving CAF/CMF regimen (see above) had cryotherapy on the single day of treatment
Outcomes • Oral mucositis: WHO 0 to 4 scale assessed separately by participants and clinicians (first cycle-only
reported, assessed daily by participants or on days 1, 5, 14 and 21 for the 5-day regimen (MAYO) and
days 7, 14 and 21 for the single-day regimens (CAF/CMF), maximum score reported)
Obtained from correspondence:
• Interruptions to cancer treatment: (assessed over first 2 cycles, reported as both event (dichotomous)
data and continuous data in the form of mean number of days of interruption)
• Oral pain: 1 to 5 scale relating to duration of pain experience (1 = never, 2 = one day of week, 3 = 2 to
3 days of week, 4 = most of week, 5 = 7 days of week)
Notes Sample size calculation: not reported
Adverse effects: 8 (20%) of participants in the cryotherapy group complained of chills
Funding: "This work was supported by the department of research, Mashhad University of Medical
Science"
Declarations/conflicts of interest: not reported
Data handling by review authors: clinician judgement of oral mucositis was preferred over partic-
ipant judgement as we deemed that this may be more objective and less biased; oral pain was mea-
sured in a different way to the other studies measuring intensity/severity of pain and therefore it is not
appropriate to meta-analyse using standardised mean difference, so we have presented the data in an
additional table
Other information of note: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was performed by the use of a random numbers table"
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: "Randomization was performed by the use of a random numbers table"
Correspondence: "We designed a list that numbered from 100 to 180. Then an
external person involved assigning a letter (A, AB, B, and BA) to the each num-
ber randomly. The entire investigator was blinded about number and letters.
As patients enrolled for study, the external person enters the patient's code in
the list. In summary, we used an external person to allocate patient to the in-
tervention or control group"
Comment: third-party randomisation should have ensured that the allocation
sequence was not manipulated
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Not possible to blind participants and personnel to allocated groups
Heydari 2012  (Continued)
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Heydari 2012  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Kerman, Iran
Number of centres: 1
Study duration: not reported
Participants Inclusion criteria: partial or complete exposure of head and neck to radiation; minimum radiation
dose of 2500 to 3000 cGy (trial registry says Gy) per session; beginning radiotherapy at the start of the
study and continuing constantly for the following 2 weeks
Exclusion criteria: existing oral mucositis; systemic disease or medication affecting oral condition; less
than 15 or more than 55 years of age
Cancer type: head and neck (not reported by group)
Cancer treatment: radiotherapy to the head and neck
Any other potentially important prognostic factors: no statistically significant difference between
groups in smoking status or education level
Age at baseline (years): Gp A: mean 42.9 (SD 14.9); Gp B: mean 49.1 (SD 15.4)
Gender: 57.5% male overall and reports that there were no statistically significant differences between
groups
Number randomised: 40 (Gp A: 20; Gp B: 20)
Number evaluated: 40 (Gp A: 20; Gp B: 20)
Interventions Comparison: cryotherapy versus no treatment
Gp A: ice cubes placed in mouth and sucked for 5 min before radiotherapy and for a further 5 min after
the session
Gp B: standard oral care
Both groups received standard oral care (use of soN toothbrush, nonabrasive toothpaste and dental
floss twice daily)
Compliance: only states "no lapse during the study"
Kakoei 2013 
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Duration of treatment (intended): 10 min per day for 2 weeks
Outcomes • Oral mucositis: 0 to 4 scale assessed separately by participants and clinicians (very similar to WHO
scale and NCI common toxicity criteria - based on methods of Mahood 1991) (assessed on days 1, 7
and 14 and reported as a mean on each separate assessment day)
• Oral pain: scale not mentioned (assessed days 1, 7 and 14 and reported as a mean on each separate
assessment day)
Notes Sample size calculation: 80% power at 5% significance level to detect a 40% difference in treatment
effect (as there were no drop-outs, it is assumed that this was achieved)
Adverse effects: not reported but presumably none were expected due to the 5-min periods of
cryotherapy
Funding: "This study was financially supported by the Office of Vice Chancellor for Research of Kerman
University of Medical Sciences"
Declarations/conflicts of interest: not reported
Data handling by review authors: we report MD and 95% CI for mucositis severity in an addition-
al table; physician-judged mucositis rating was preferred over participant judgement as we deemed
that this may be more objective and less biased; we used the data on day 14 due to the highest control
group mean; we were unable to use the oral pain data as the scale was not described
Other information of note: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The participants were divided into experimental and control groups
using block randomization technique with the formula of AABB, ABAB, ABBA,
BBAA, BABA, and BAAB"
Comment: random sequence appears to have been adequately generated
Allocation concealment
(selection bias)
Unclear risk Quote: "The participants were divided into experimental and control groups
using block randomization technique with the formula of AABB, ABAB, ABBA,
BBAA, BABA, and BAAB"
Comment: insufficient information to determine whether or not the random
sequence was adequately concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses
Selective reporting (re-
porting bias)
High risk Oral pain not mentioned in the trial registry record and not described in the
methods of the published trial report. It is possible that this was reported be-
cause it showed favourable results for cryotherapy
Kakoei 2013  (Continued)
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Other bias Low risk No other sources of bias are apparent
Kakoei 2013  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Gaziantep, Turkey
Number of centres: 1
Study duration: not reported
Participants Inclusion criteria: due to receive first course of chemotherapy; healthy oral mucosa; no dental prob-
lems
Exclusion criteria: receiving more than 1 combination chemotherapy course or antineoplastic drug
treatment with half-life of 30 min or more; discomfort in the mouth; head-neck cancer
Cancer type: gastric 33.3%; colon 33.3%; rectal 16.9%; pancreatic 9.9%; unknown 6.6% (equal num-
bers per group); stage of disease equally distributed between groups
Cancer treatment: 5FU and LV
Any other potentially important prognostic factors: education level, denture wearers, toothbrush-
ing habits, smoking status, nutrition, dry mouth, lack of appetite and systemic disease all equally dis-
tributed between groups
Age at baseline (years): not reported
Gender: 50% male in both groups
Number randomised: 60 (Gp A: 30; Gp B: 30)
Number evaluated: 60 (Gp A: 30; Gp B: 30)
Interventions Comparison: cryotherapy versus routine care
Gp A: ice chips placed in mouth 5 min before 5FU + LV, during treatment and within 15 min after treat-
ment, for total 30 min; continuously swished around, then replenished before the previous ice had
completely melted; whole procedure repeated for 5 consecutive days
Gp B: routine care
All participants were asked to remove dentures
Compliance: "Oral cryotherapy was tolerated well by the patients. The majority of the patients report-
ed that they managed to keep the oral cavity constantly cooled most of the time that the chemothera-
py treatment was administered. Patients who experienced discomfort during the cryotherapy applica-
tion continued their treatment after a maximum 30-60 s break"
Duration of treatment (intended): 30 min per day for 5 days (first cycle only)
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed and reported on days 7, 14 and 21 - i.e. not reported as
maximum score per participant)
Notes Sample size calculation: not reported
Adverse effects: "The patients completed the procedure quite comfortably, without any problems
during the application"
Funding: not reported
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Declarations/conflicts of interest: "None declared"
Data handling by review authors: data were reported separately on the 3 assessment days rather
than a maximum score per person over the whole assessment period. We used the data on the day with
the highest incidence of grades > 0 (day 14), although we are not sure how valid this is because there
was still a high incidence of severe oral mucositis at day 21
Other information of note: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomisation was performed by MedCalc software to give equal
chance to assign each intervention group"
Comment: computer generated randomisation so probably done adequately
Allocation concealment
(selection bias)
Unclear risk Quote: "Randomisation was performed by MedCalc software to give equal
chance to assign each intervention group"
Comment: insufficient information to determine whether or not the random
sequence was adequately concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Katranci 2012  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Seattle, USA
Number of centres: 1
Study duration: August 2003 to June 2005
Participants Inclusion criteria: minimum age 18 years with multiple myeloma; scheduled to receive single-agent
high-dose melphalan (200 mg/m2) followed by autologous PBSCT 2 days later
Exclusion criteria: previous autologous PBSCT
Cancer type: haematological (multiple myeloma)
Lilleby 2006 
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Cancer treatment: high-dose melphalan (200 mg/m2) followed by autologous PBSCT
Any other potentially important prognostic factors: not reported
Age at baseline (years): Gp A: median 59 (range 51 to 71); Gp B: median 57 (range 33 to 72)
Gender: Gp A: 76.2% male; Gp B: 63.2% male
Number randomised: 41 (Gp A: 21; Gp B: 20)
Number evaluated: 40 (Gp A: 21; Gp B: 19) (above figures for age and gender are for evaluated partici-
pants)
Interventions Comparison: cryotherapy versus saline rinse
Gp A: 2 days before stem cell infusion, 1 ounce of ice chips held in mouth 30 min prior to beginning sin-
gle-agent high-dose melphalan (200 mg/m2) infusion, replenished when melted, procedure continued
for 6 hours after the end of the 30-min melphalan infusion
Gp B: 2 days before stem cell infusion, 1 ounce of room temperature normal saline swished around the
mouth and spat out 30 min prior to beginning single-agent high-dose melphalan (200 mg/m2) infusion,
procedure repeated every 30 min for 6 hours after the end of the 30-min melphalan infusion
All participants instructed not to eat or drink anything extremely hot or cold during cryotherapy/saline
treatment
Compliance: 14 participants had at least 5 hours of cryotherapy, and 2 had at least 2 hours, whilst 5 did
not report the duration. Some participants stopped using the ice chips due to their coldness. Average
frequency of use: cryotherapy: 1 cup/hour; saline: 1 to 4 rinses/hour
Duration of treatment (intended): 7 hours
Outcomes • Oral mucositis: NCI-CTC 0 to 4 scale (assessed until 30 days after cryotherapy/saline administration,
maximum score reported)
• Normalcy of diet: duration of TPN (assessed until 30 days after cryotherapy/saline administration)
• Duration of IV narcotic use (assessed until 30 days after cryotherapy/saline administration)
• Duration of hospitalisation (assessed until 30 days after cryotherapy/saline administration)
• Weight loss (not an outcome of this review)
• First day 30% of calorific needs met (not an outcome of this review)
Patient-reported events:
• Mouth and throat pain: 0 to 10 scale (assessed daily by questionnaire until 30 days after cryothera-
py/saline administration)
• Adverse effects of cancer treatment: difficulties swallowing, drinking, eating, talking, sleeping and
taste disturbance (not outcomes of this review)
Notes Sample size calculation: required sample size was achieved ("sample size of 40 was chosen to provide
91% power to observe a statistically significant difference (at the 2-sided significance level of 0.05) in
the probability of grades 3–4 mucositis under the assumption that the true probabilities of severe mu-
cositis are 0.25 for patients receiving ice chips and 0.75 for patients receiving normal saline")
Adverse effects: not reported, only refers to some participants that stopped using the ice chips due to
their coldness
Funding: "This work was supported by Friends of Jose Carreras International Leukemia Foundation
Presidential Award, NCI P01 CA-18029"
Declarations/conflicts of interest: not reported
Data handling by review authors: for patient-reported oral pain, we used the mean, number of par-
ticipants and P value to calculate a single SD to be used for both groups (we used the overall mean
Lilleby 2006  (Continued)
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pain scores rather than the number of days of pain or the mean of the highest value); only medians and
ranges presented for the outcomes days of TPN, IV narcotics and hospitalisation, so we present the re-
sults, as reported in the study report, in an additional table
Other information of note: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "patients...were randomized to receive either ice chips or room tem-
perature normal saline rinses"
Correspondence: "randomisation was accomplished using a computer pro-
gram designed by one of our statisticians"
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: "patients...were randomized to receive either ice chips or room tem-
perature normal saline rinses"
Correspondence: "Central randomization from the protocol office"
Comment: central randomisation should have ensured that the allocation se-
quence was not manipulated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 1 randomised participant, from the control group, was not included in
the analyses. The participant withdrew consent because he wanted to use ice
chips
Selective reporting (re-
porting bias)
Low risk Although the data for some outcomes of this review were not presented in a
way amenable to meta-analysis, this is unlikely to be due to bias
Other bias Low risk No other sources of bias are apparent
Lilleby 2006  (Continued)
 
 
Methods Trial design: cross-over (2 arms)
Location: USA
Number of centres: unclear (multicentre)
Study duration: not reported
Participants Inclusion criteria: first ever course of chemotherapy
Exclusion criteria: not reported
Cancer type: not reported but must be solid due to chemotherapy regimen
Mahood 1991 
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Cancer treatment: 5FU and LV
Any other potentially important prognostic factors: not reported
Age at baseline (years): not reported
Gender: not reported
Number randomised: 95 (Gp A: 50; Gp B: 45)
Number evaluated: 93 (Gp A: 50; Gp B: 43)
Interventions Comparison: cryotherapy versus no treatment
Gp A: ice chips placed in mouth 5 min before receiving 5FU (425 mg/m2) and LV (20 mg/m2) by IV over
a few minutes, and continuously swished around, then replenished before the previous ice had com-
pletely melted, for total 30 min, whole procedure repeated for 5 consecutive days
Gp B: 5FU (425 mg/m2) and LV (20 mg/m2) only for 5 consecutive days
All participants were asked to remove dentures
Compliance: not clearly reported. Only states "well tolerated by most patients"
Duration of treatment (intended): 30 min per day for 5 days (first cycle only)
Outcomes • Oral mucositis: physician judgement and participant judgement both on a 0 to 4 scale (very similar
to WHO scale and NCI common toxicity criteria) (physician's judgement assessed by historical means
approximately 1 month after treatment initiation, maximum score reported)
• Duration of oral mucositis (not an outcome of this review)
Notes Sample size calculation: not reported
Adverse effects: "A few patients noted mild, temporary mouth numbness or an "ice cream" headache
which rapidly resolved after cessation of cryotherapy. Also, some patients ascribed nausea to the oral
ice chips (the nausea may have actually been from the 5FU)"
Funding: "supported in part by Public Health Service grants...and Community Clinical Oncology Pro-
gram grants"
Declarations/conflicts of interest: not reported
Data handling by review authors: we only used the data from the first treatment cycle (rather than
cross-over data); physician judgement of oral mucositis was preferred over participant judgement as
we deemed that this may be more objective and less biased
Other information of note: mean oral mucositis score reported by smoking status for each group for
the first cycle only (smokers had statistically significantly lower mean oral mucositis score than non-
smokers, but data not available for all participants)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Prior to therapy, patients were stratified by age and whether or not
they had dentures. They were then randomized to a control arm or to receive
cryotherapy"
Comment: insufficient information to determine method of random sequence
generation
Mahood 1991  (Continued)
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Allocation concealment
(selection bias)
Unclear risk Quote: "Prior to therapy, patients were stratified by age and whether or not
they had dentures. They were then randomized to a control arm or to receive
cryotherapy"
Comment: insufficient information to determine whether or not the random
sequence was adequately concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 2 randomised participants, both from the control group, were not includ-
ed in the physician-judged oral mucositis analyses. We do not believe that this
could pose a risk of bias significant enough to have led to a distortion of the
true intervention effect
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Mahood 1991  (Continued)
 
 
Methods Trial design: cross-over (2 arms)
Location: USA
Number of centres: unclear (multicentre)
Study duration: not reported
Participants Inclusion criteria: first course of chemotherapy
Exclusion criteria: not reported
Cancer type: not reported but must be solid due to chemotherapy regimen
Cancer treatment: 5FU and LV, different dosages taken orally or by IV, equally distributed between
groups due to stratification
Any other potentially important prognostic factors: participants were stratified by smoking status,
dentures and institution/centre; gum condition not used for stratification but Gp B (60 min cryothera-
py) had worse gums at baseline (P = 0.02)
Age at baseline (years): Gp A: median 65 (range 24 to 79); Gp B: median 65 (range 25 to 85)
Gender: Gp A: 55% male; Gp B: 51% male
Number randomised: 179 (Gp A: 90; Gp B: 89)
Number evaluated: 178 (Gp A: 89; Gp B: 89)
Interventions Comparison: 30 min of cryotherapy versus 60 min of cryotherapy
Rocke 1993 
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Gp A: ice chips placed in mouth 5 min before receiving 5FU and LV, and continuously swished around,
then replenished before the previous ice had completely melted, for total 30 min, whole procedure re-
peated for 5 consecutive days
Gp B: as above but for total 60 min
All participants were asked to remove dentures
Compliance: well tolerated with high degree of compliance. Only a few participants stopped cryother-
apy early (due to nausea, headache or chills). Many participants in the 60-min group were unhappy
with the duration of cryotherapy, indicating that 30 min of cryotherapy is preferred
Duration of treatment (intended): 30 or 60 min per day for 5 days (first cycle only)
Outcomes • Oral mucositis: physician judgement and participant judgement both on a 0 to 4 scale (very similar
to WHO scale and NCI common toxicity criteria) (physician's judgement assessed by historical means
approximately 1 month after treatment initiation, maximum score reported)
• Duration of oral mucositis (not an outcome of this review)
Notes Sample size calculation: not reported
Adverse effects: only a few participants stopped cryotherapy early (due to nausea, headache or chills)
Funding: "supported in part by Public Health Service grants...from the National Cancer Institute, De-
partment of Health and Human Services"
Declarations/conflicts of interest: not reported
Data handling by review authors: we only used the data from the first treatment cycle (rather than
cross-over data); physician judgement of oral mucositis was preferred over participant judgement as
we deemed that this may be more objective and less biased
Other information of note: in exploratory analyses, age over 65 years was statistically significantly (P <
0.001) associated with severity of mucositis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomized to receive cryotherapy for either 30 or 60
minutes"
Comment: insufficient information to determine method of random sequence
generation
Allocation concealment
(selection bias)
Unclear risk Quote: "Patients were randomized to receive cryotherapy for either 30 or 60
minutes"
Comment: insufficient information to determine whether or not the random
sequence was adequately concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Rocke 1993  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 1 randomised participant, from the cryotherapy group, was not included
in the analyses due to an unrelated medical problem
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Rocke 1993  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Toronto, Canada
Number of centres: 1
Study duration: May to December 2007
Participants Inclusion criteria: minimum 18 years of age; able to read and understand instructions on oral
cryotherapy and basic oral care in English; diagnosis of multiple myeloma; due to receive high-dose
melphalan (200 mg/m2); due to receive growth factors as part of treatment protocol; no pre-existing
oral disease
Exclusion criteria: previous radiotherapy to the head and neck region; amyloidosis (when abnormal
proteins collect together and build up in tissues/organs) involving the heart, kidneys, or tongue; receiv-
ing investigational drugs during the trial period
Cancer type: haematological (multiple myeloma)
Cancer treatment: high-dose melphalan (200 mg/m2) followed by autologous SCT
Any other potentially important prognostic factors: college/university educated: Gp A: 43%; Gp B:
16%; smokers: Gp A: 17%; Gp B: 9%; drinks alcohol: Gp A: 35%; Gp B: 27%
Age at baseline (years): Gp A: mean 56 (SD 8.9) (range 43 to 72); Gp B: mean 62 (SD 7.7) (range 43 to 72)
Gender: Gp A: 61% male; Gp B: 55% male
Number randomised: 46 (Gp A: 23; Gp B: 23)
Number evaluated: 45 (Gp A: 23; Gp B: 22)
Interventions Comparison: cryotherapy versus no treatment
Gp A: on day -1 (the day before autologous SCT), ice chips held in mouth 5 min prior to receiving high-
dose melphalan (200 mg/m2), replenished before melted, procedure continued until 5 min after mel-
phalan infusion, for total 60 min. Basic oral care also received (described below) from day -1
Gp B: on day -1, basic oral care began (described below)
All participants received high-dose melphalan on day -1 and SCT the following day (day 0). On aver-
age, participants stayed in hospital for 14 days after SCT. During the engraftment period, patients also
received similar treatment and care protocols: prophylactic antimicrobial, antiviral and antacid (day
1), and growth factor (granulocyte colony-stimulating factor) (day 7); and basic oral care protocol (day
-1). Oral care protocol consisted of regular oral assessment and documentation, patient education on
OM, and training in oral self care (toothbrushing with Toothette sponges dipped in sodium bicarbonate
mouthwash, mouthrinsing with sodium bicarbonate mouthwash, and application of moisturiser to lips
and oral cavity).
Salvador 2012 
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Compliance: all participants were able to perform the basic oral care procedures and all participants in
the cryotherapy group complied with the intervention
Duration of treatment (intended): basic oral care from day -1 to day 12 (14 days); oral cryotherapy for
60 min on day -1
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed on days 3, 6, 9 and 12 and reported as a mean on each sep-
arate assessment day - not reported for day 3 as OM had not yet developed); we requested maximum
score experienced per participant over the whole study period and the author provided this data
• Oral pain: 0 to 10 VAS (assessed on days 3, 6, 9 and 12 and reported as an overall mean score)
• Duration of hospital stay (mean number of days, measured as total number of days from admission
to discharge - all participants were treated as inpatients)
• Normalcy of diet: functional intake of food and fluids on 1 (solids) to 5 (nothing by mouth) scale (as-
sessed on days 3, 6, 9 and 12 and reported in a mixed-effects regression analysis)
• Time to onset, duration and time to resolution of oral mucositis (not an outcome of this review)
• Amount of opioid analgesics used (not an outcome of this review)
Notes Sample size calculation: 17 participants per group needed to detect an effect size of 1 (presumably
the authors mean a MD of 1 on the WHO scale) at 80% power and 5% significance
Adverse effects: 4 participants (17.4%) in the cryotherapy group experienced side effects (teeth sensi-
tivity and chills)
Funding: "The authors acknowledge the financial support of the University Health Network Nursing
Research and Canadian Nurses Foundation for the successful implementation of the project"
Declarations/conflicts of interest: "The authors have nothing to disclose and declare no conflicts of
interest"
Data handling by review authors: the authors provided the maximum score experienced per partici-
pant over the whole study period; we were unable to use the data on normalcy of diet
Other information of note: although the authors report that the MD of 0.71 in OM severity (at day 9)
was statistically significant, they state that it is not clinically significant because most participants only
had OM grades of 0 to 1; conversely, the authors report that the difference in days of hospital stay was
not statistically significant, but that the difference of approximately 1 day is clinically significant; we
note an error in Table 2 where the mean in the control group at day 6 should be 0.5 rather than 0.05
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Participants were allocated based on a randomization process per-
formed by the biostatistics staE at the study site, using consecutively num-
bered sealed envelopes containing a computer-generated random number list
patient assignment"
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: "Participants were allocated based on a randomization process per-
formed by the biostatistics staE at the study site, using consecutively num-
bered sealed envelopes containing a computer-generated random number list
patient assignment"
Comment: these methods should have ensured that the allocation sequence
was not manipulated
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Not possible to blind participants and personnel to allocated groups
Salvador 2012  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Although described as blinded, the subjective elements in the scale used to
measure oral mucositis could have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 1 randomised participant, from the control group, was not included in the
analyses due to an adverse event related to the melphalan on the day of its ad-
ministration
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Salvador 2012  (Continued)
 
 
Methods Trial design: parallel (3 arms)
Location: Denmark
Number of centres: unclear (appears to be multicentre)
Study duration: 2001 to 2005
Participants Inclusion criteria: gastric or colorectal cancers; due to receive first course of chemotherapy; healthy
oral mucosa
Exclusion criteria: history of head and neck radiotherapy; symptoms of any infections; history of den-
tal or mouth discomfort when consuming hot/cold food and drinks
Cancer type: approximately 95% colorectal cancer in each group, with the remainder having gastric
cancer
Cancer treatment: 5FU and LV
Any other potentially important prognostic factors: participants were stratified by age, smoking sta-
tus and dentures; performance status score was equally distributed between groups
Age at baseline (years): Gp A: 40 or older = 97%, median 62 (range 36 to 84); Gp B: 40 or older = 95%,
median 61 (range 30 to 81); Gp C: 40 or older = 92%, median 62 (range 28 to 82)
Gender: Gp A: 60% male; Gp B: 53% male; Gp C: 53% male
Number randomised: 225 (Gp A: 75; Gp B: 75; Gp C: 75)
Number evaluated: reported in the study: 206 (Gp A: 67; Gp B: 66; Gp C: 73); data available for OM inci-
dence: 197 (Gp A: 63; Gp B: 64; Gp C: 70)
Interventions Comparison: cryotherapy versus saline rinse (placebo version of chlorhexidine) versus chlorhexi-
dine rinse
Gp A: crushed ice placed in mouth 10 min before receiving 5FU (425 mg/m2) and LV (20 mg/m2) by IV,
and for 35 min after the start of infusion (total 45 min), whole procedure repeated for 5 consecutive
days every 4 weeks
Gp B: same cancer treatment but saline mouthwash (with same taste additives as Gp C), 10 ml swished
around the mouth for 1 min, 3 times per day for 21 days
Gp C: same cancer treatment but chlorhexidine 0.1% mouthwash, same schedule as Gp B
Sorensen 2008 
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All participants were asked to remove dentures; participants were "instructed to continue prophylaxis
in case OM occurred, which was treated according to the discretion of the respective investigators"
Compliance: (complete) Gp A: 87%; Gp B: 80%; Gp C: 75%; (partial) Gp A: 13%; Gp B: 20%; Gp C: 25%
Duration of treatment (intended): 45 min per day for 5 days per chemotherapy cycle (cryotherapy); 3
min per day for 21 days per chemotherapy cycle (chlorhexidine and saline rinses)
Outcomes • Oral mucositis: NCI-CTC (2.0) 0 to 4 scale (first cycle-only reported at day 28, participants kept daily
record and self-evaluated OM by questionnaire on days 14 and 28, physician also scored OM on days 14
and 28, participant score was reported as there were no statistically significant differences between
participant and physician scores, maximum score reported)
• Duration of oral mucositis (not an outcome of this review)
• Compliance (not an outcome of this review)
• Haematologic toxicity (not an outcome of this review)
Notes Sample size calculation: considering a 15% decrease in incidence of grade 3 to 4 OM as being clinical-
ly meaningful, with 80% power and at the 5% significance level, 75 patients required per group. There-
fore, considering drop-outs, required sample size was not achieved
Adverse effects: taste disturbance: Gp A: 24/67 (36%); Gp B: 25/66 (38%); Gp C: 35/73 (48%); headache:
Gp A: 14/67 (21%); Gp B: 9/66 (14%); Gp C: 10/73 (14%)
Funding: "Supported by a grant from the National University Hospitals Research Foundation in Den-
mark"
Declarations/conflicts of interest: not reported
Data handling by review authors: the study authors report that data were available on 206 partici-
pants, however, for OM incidence, some of this number of participants are not given a grade and are
listed as 'NA' (abbreviation not explained). We subtracted the 'NA' participants from the total number
of participants and have addressed this problem under 'Incomplete outcome data (attrition bias)'
Other information of note: smoking status, performance status and being aged 40 or older (under-
powered - only 11 participants less than 40) were not statistically significantly associated with severity
of OM
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were stratified...and randomized after informed consent to 1
of 3 prophylactic regimens"
Comment: insufficient information to determine method of random sequence
generation
Allocation concealment
(selection bias)
Unclear risk Quote: "Patients were stratified...and randomized after informed consent to 1
of 3 prophylactic regimens"
Comment: insufficient information to determine whether or not the random
sequence was adequately concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Sorensen 2008  (Continued)
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk For OM incidence, 12% of randomised participants were not included in the
analysis (Gp A: 16%; Gp B: 15%; Gp C: 9%). Reasons are not reported but
there is a potential risk of bias if this differential drop-out is related to out-
comes/prognosis
Selective reporting (re-
porting bias)
Low risk Data for outcomes of this review were reported appropriately
Other bias Low risk No other sources of bias are apparent
Sorensen 2008  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Uppsala, Sweden
Number of centres: 1
Study duration: January 2002 to August 2004
Participants Inclusion criteria: more than 18 years of age; able to communicate in Swedish; about to receive BMT
Exclusion criteria: not reported
Cancer type: 1 participant per group had testicular cancer, the remainder had haematological cancers
Cancer treatment: type of chemotherapy prior to BMT was fairly equally distributed between groups;
participants were stratified by autologous BMT (both groups 79.5%) versus allogeneic URD BMT (both
groups 20.5%)
Any other potentially important prognostic factors: tobacco use equally distributed between
groups (Gp A: 17.9%; Gp B: 15.4%)
Age at baseline (years): Gp A: mean 49.8 (SD 14.4); Gp B: mean 54.3 (SD 11)
Gender: Gp A: 66.7% male; Gp B: 48.7% male
Number randomised: 78 (Gp A: 39; Gp B: 39)
Number evaluated: 78 (Gp A: 39; Gp B: 39)
Interventions Comparison: cryotherapy versus no treatment
Gp A: prior to BMT (unclear how far in advance); ice chips placed in mouth or rinsing with ice-cold water
starting 5 min before receiving chemotherapy by IV, and replenished for the duration of the chemother-
apy session
Gp B: chemotherapy prior to BMT
All participants received standard oral care during BMT
Compliance: 58% to 75% of the participants reported that they kept the mouth constantly cooled for
the entire duration of the chemotherapy; 71% to 100% did so more than half the time
Duration of treatment: not reported (variable and dependent on type of chemotherapy)
Outcomes • Oral mucositis: OMAS (seeAppendix 8 for details of scale) (assessed once daily for 21 days after start
of chemotherapy by nurse, mean score reported on each day, reported separately for autologous/al-
logeneic BMT but no overall score reported)
Svanberg 2007 
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• Oral mucositis: WHO 0 to 4 scale (incidence of severe mucositis i.e. grade 3 to 4, assessed once daily
for 21 days after start of chemotherapy) (outcome reported in secondary publication); we requested
maximum score experienced per participant over the whole study period and the author provided this
data
• Oral pain: 0 to 10 VAS (assessed twice daily (morning and afternoon) for 21 days after start of
chemotherapy, reported verbally to nurse)
• Duration of opioid use (mean number of days, assessed over period of 31 days after start of chemother-
apy from medical records)
• Duration of hospital stay (outcome reported in secondary publication) (mean number of days, as-
sessed over period of 31 days after start of chemotherapy)
• Normalcy of diet: incidence of TPN and duration of TPN (outcome reported in secondary publication)
(we used mean number of days, assessed over period of 31 days after start of chemotherapy)
• Weight loss (not an outcome of this review)
• Duration of fever (not an outcome of this review)
• Antibiotic use (not an outcome of this review)
• Total dose of opioids (not an outcome of this review)
• White blood cell counts and c-reactive protein levels (not outcomes of this review)
Notes Sample size calculation: 36 participants per group needed for 80% power at 5% significance level
(based on outcome 'duration of IV opioids')
Adverse effects: 7 (18%) of participants found cryotherapy unpleasant, with 4 of those (10%) finding it
very unpleasant due to shooting pain from the teeth
Funding: "This study was in part supported by FoU funds, Uppsala läns landsting, Sweden"
Declarations/conflicts of interest: not reported
Data handling by review authors: we were unable to use the OMAS score but the authors provided full
data for oral mucositis on the WHO scale; oral pain was not reported adequately so we were unable to
report on this outcome
Other information of note: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A random assignment to EXP or CTR group was performed in blocks of
six outside of the clinic by an independent researcher"
Comment: if using block-randomisation, it could be assumed that the inde-
pendent researcher would have done this adequately
Allocation concealment
(selection bias)
Low risk Quote: "A random assignment to EXP or CTR group was performed in blocks of
six outside of the clinic by an independent researcher"
Comment: third-party randomisation should have ensured that the allocation
sequence was not manipulated
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Svanberg 2007  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses
Selective reporting (re-
porting bias)
High risk Oral mucositis using OMAS and oral pain inadequately reported. Data are pre-
sented in the text for mucositis scores on day 10 (autologous patients) and
day 16 (allogeneic patients), and this appears to be based on statistical sig-
nificance. The study authors have since provided full data on the WHO scale.
Therefore, our rating for this domain is based on the fact that the text only
states that there was no significant differences for oral pain
Other bias Low risk 45 staE members assessed mucositis using the OMAS instrument. Calibration
is not mentioned. However, we were unable to use any data for this outcome
so we can discount any potential bias
Svanberg 2007  (Continued)
 
 
Methods Trial design: parallel (3 arms)
Location: San Antonio, Texas, USA
Number of centres: 1
Study duration: first subject randomised August 2009; last subject randomised January 2013
Participants Inclusion criteria: minimum 18 years of age; diagnosis of multiple myeloma and scheduled to receive
high-dose melphalan (70 to 100 mg/m2/day) for 2 days, as a single agent, for conditioning regimen pri-
or to HSCT
Exclusion criteria: received palifermin (Kepivance) in the past 30 days; received any investigational
drug in the past 30 days; received radiation therapy in the past 30 days; oral mucositis at the time of
randomisation; altered mental status precluding understanding of the informed consent process and/
or completion of the necessary assessments
Cancer type: haematological (multiple myeloma)
Cancer treatment: high-dose melphalan, prior to autologous HSCT
Any other potentially important prognostic factors: no differences between groups in race/ethnici-
ty, Karnofsky performance score, diabetes, denture wearing, smoking status
Age at baseline (years): Gp A: median 62 (range 39 to 75); Gp B: median 61.5 (range 43 to 70)
Gender: both groups 95% male
Number randomised: 78 (Gp A: 40; Gp B: 38) (numbers are for the 2 groups of interest to this review)
Number evaluated: 78 (Gp A: 40; Gp B: 38)
Interventions Comparison: cryotherapy plus saline rinse versus saline rinse
The 3rd group involved using supersaturated calcium phosphate rinse (Caphosol®) but we have exclud-
ed this arm because the co-intervention of cryotherapy plus saline may confound the comparison. The
comparison of this 3rd group with the saline group will be included in our review of basic oral care in-
terventions for the prevention of oral mucositis in cancer patients
Gp A: on day -2 and -1 (HSCT was on day 0), approximately 1 ounce of crushed ice held in the mouth 15
min prior to the initiation of melphalan infusion, replenished as soon as it had completely melted, this
procedure continued during the melphalan infusion and for 90 min after the end of the infusion. After
completion of cryotherapy, standard care was followed until the end of the study (see Gp B below)
Toro 2013 
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Gp B: standard care (0.9% sodium chloride irrigation solution): rinsing of mouth twice, with 1 ounce (30
ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
Compliance: 100% compliance with cryotherapy but 3 subjects from the saline group refused to follow
protocol but were kept in study
Duration of treatment (intended): 2 consecutive days (exact duration of cryotherapy sessions un-
clear)
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed daily until resolution or hospital discharge up to a maxi-
mum of 30 days, maximum score reported)
• Oral pain: scale not reported
• Narcotic use: unclear whether or not reported as duration of opioid use or amount of opioid use
• Quality of life: Patient-Reported Oral Mucositis Symptom (PROMS) scale (assessed daily until resolu-
tion of oral mucositis)
• Duration of oral mucositis (not an outcome of this review)
Notes Sample size calculation: "This study will achieve a power of 80% to detect a 0.30 reduction in the pro-
portion of subjects experiencing mucositis relative to saline with 55 subjects per arm and relative to
Caphosol with 43 subjects per arm, using 2-sided pairwise Pearson chi-square testing with the Bonfer-
roni corrected significance level of 0.017 (PASS, Version 08.0.8, NCSS Kaysville, Utah 2008). Assuming no
loss to follow-up and complete data, the required sample size for this study is therefore 55 subjects per
arm, giving a total required sample size of 165 subjects. The study was terminated early because of eth-
ical concerns after an interim analysis"
Adverse effects: no serious adverse events
Funding: "There was no outside funding for this study"
Declarations/conflicts of interest: "No conflict of interest for all authors"
Data handling by review authors: the oral mucositis incidence of each WHO grade was presented as
percentages so we converted this to numbers of persons experiencing each grade
Other information of note: only abstracts available but the authors have provided extra information
through email correspondence to allow inclusion in this review. Study report is currently being written
up and secondary outcome data have not yet been analysed, so we will include these in the next up-
date of the review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "were randomized to the above mentioned groups"
Correspondence: "The computer program used to generate these sheets
makes block stratified assignments with user selected block size"
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: "were randomized to the above mentioned groups"
Correspondence: "The random sequence list was kept at the principal inves-
tigator's office and only when a subject had signed the informed consent and
agrees to participate in any of the three arms of the study, was the research co-
ordinator able to look at the list and assigned the treatment"
Comment: these methods should have ensured that the allocation sequence
was not manipulated
Toro 2013  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk The subjective elements in the scale used to measure oral mucositis could
have introduced bias into the assessments
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses
Selective reporting (re-
porting bias)
Low risk This domain is not yet applicable as the study report is currently being written
up
Other bias Low risk No other sources of bias are apparent
Toro 2013  (Continued)
 
 
Methods Trial design: parallel (4 arms)
Location: Beijing, China
Number of centres: 1
Study duration: June 2009 to May 2010
Participants Inclusion criteria: patients due to receive high-dose MTX
Exclusion criteria: not reported
Cancer type: osteosarcoma (bone cancer)
Cancer treatment: MTX plus vincristine plus LV
Any other potentially important prognostic factors: not reported
Age at baseline (years): not reported
Gender: not reported
Number randomised: 147 (Gp A: 52; Gp B: 66; Gp C: 29) (numbers are for the 3 groups of interest to this
review)
Number evaluated: 147 (Gp A: 52; Gp B: 66; Gp C: 29)
Interventions Comparison: cryotherapy versus LV versus high dose LV
The 4th group involved using the standard LV dose once OM symptoms appeared. This constitutes
treatment rather than prevention and therefore we excluded this arm
Gp A: from the start of MTX, 100 ml ice water to be used for gargling (amount per gargle and frequency
of gargling not specified), for 3 consecutive days
Gp B: from the start of MTX, 3 mg LV dissolved in 100 ml water to be used for gargling per day, for 3 con-
secutive days (amount per gargle not specified)
Gp C: from the start of MTX, 200 mg LV dissolved in 40 ml water to be used for gargling per day (10 ml 4
times daily), for 3 consecutive days
Zhang 2011 
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All participants received MTX (10 g/m2 administered by IV over 4 to 6 hours), vincristine (2 mg), and
LV (12 mg every 6 hours, beginning 6 to 8 hours after finishing the MTX IV drop - it is not clear from the
translation of the paper how long this occurred for or indeed if was just a single dose 6 to 8 hour after
MTX). From 1 day prior to the start of MTX, participants had diuresis and alkalinising for 3 consecutive
days, plus oral sodium bicarbonate (1 g) and allopurinol (200 mg) both 3 times daily for 4 consecutive
days
Compliance: not reported
Duration of treatment (intended): 3 days (actual length of time the ice water or LV was held in the
mouth is not reported)
Outcomes • Oral mucositis: WHO and NCI-CTC (3.0) 0 to 4 scale (assessed 1 and 10 days after start of chemotherapy
- reported as incidence of any OM over the study period and also by severity on the 4th day after MTX)
• Duration of oral mucositis (not an outcome of this review)
• MTX concentration in saliva (not an outcome of this review)
Notes Sample size calculation: not reported
Adverse effects: not reported
Funding: not reported/not obtained from translation
Declarations/conflicts of interest: not reported/not obtained from translation
Data handling by review authors: we have used the data from Table 1 for the analysis of no mucosi-
tis versus any mucositis as this appears to be the incidence of any mucositis over the whole study pe-
riod, and is therefore not at risk of bias; we have used the data on severity at day 4 but it may be at risk
of bias due to selective reporting and readers should take this into consideration when interpreting the
results
Other information of note: it is unclear why the authors report OM severity at day 4, after they state
that symptoms usually occur 5 to 7 days after chemotherapy. No participants had severe OM (grades 3
or 4) on day 4. If any participants developed severe OM after day 4, then the study will not reflect this
and the incidence of severe OM in this type of study will have been underestimated. We would recom-
mend that authors report the maximum grade experienced by each participant in future publications,
or at least report a range of appropriate time points
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "patients were randomly allocated to 4 groups using a random number
table"
Comment: random sequence appears to have been adequately generated
Allocation concealment
(selection bias)
Unclear risk Quote: "patients were randomly allocated to 4 groups using a random number
table"
Comment: insufficient information to determine whether or not the random
sequence was adequately concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not possible to blind participants and personnel to allocated groups
Blinding of outcome as-
sessment (detection bias) 
High risk The subjective elements in the scales used to measure oral mucositis could
have introduced bias into the assessments
Zhang 2011  (Continued)
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All randomised participants were included in the analyses
Selective reporting (re-
porting bias)
High risk Oral mucositis was measured on the day of chemotherapy and on day 10, but
severity is reported on day 4
Other bias Low risk No other sources of bias are apparent
Zhang 2011  (Continued)
5FU = fluorouracil; autologous = patients' own cells; allogeneic = cells from donor; BMI = body mass index; BMT = bone marrow
transplantation; CI = confidence interval; EOCG = Eastern Oncology Co-operative Group; GVHD = graN-versus-host disease; HSCT =
haematopoietic stem cell transplantation; IFN = interferon; IV = intravenous; LV = leucovorin; MD = mean diEerence; MTX = methotrexate;
NCI-CTC = National Cancer Institute common toxicity criteria; OM = oral mucositis; OMAS = oral mucositis assessment scale; PBSCT =
peripheral blood stem cell transplantation; SCT = stem cell transplantation; SD = standard deviation; TPN = total parenteral nutrition; URD
= unrelated donor; VAS = visual analogue scale; VP16 = vepesid/etoposide; WHO = World Health Organization
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aisa 2005 Not RCT (historical controls)
Baydar 2005 Cross-over study. First-period data not presented
Castelino 2011 Plain versus flavoured ice. Cross-over study. First-period data not presented
de Paula Eduardo 2014 Cryotherapy plus laser versus laser. We cannot exclude the possibility of interaction between inter-
ventions and therefore we would not be confident in stating that any improved/reduced effect is
due to the cryotherapy
Karagozoglu 2005 Not RCT (participants were allocated by alternation)
Mori 2006 Not RCT (historical controls)
Nikoletti 2005 Plain versus flavoured ice versus standard care. Cross-over study. First-period data not presented
Ohyama 1994 Translated from Japanese: case series of 5 cancer patients
Papadeas 2007 Not RCT (allocation based on date of birth)
Sato 1997 Unclear if RCT. Author was contacted during previous update of this Cochrane review but we re-
ceived no response
Sato 2006 Not RCT (no mention of random allocation to groups)
RCT = randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Trial design: parallel (2 arms)
Location: Chandigarh, India
CTRI/2013/08/003906 
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Number of centres: 1
Study duration: 6 months (dates unclear from trials registry)
Participants Inclusion criteria: aged from 18 to 80 years; males or females newly diagnosed with head and neck
cancer; radical radiotherapy planned; normal mucosa
Exclusion criteria: palliative radiotherapy planned; coming for booster dose of radiation
Cancer type: head and neck
Cancer treatment: radiotherapy to the head and neck
Any other potentially important prognostic factors: unclear from trials registry
Age at baseline (years): unclear from trials registry
Gender: unclear from trials registry
Number randomised: 60 (Gp A: 30; Gp B: 30)
Number evaluated: unclear from trials registry
Interventions Comparison: cryotherapy versus no treatment
Gp A: ice cubes held in mouth for 4 min before radiotherapy and for a further 4 min after the ses-
sion
Gp B: standard oral care
All participants received standard oral care
Compliance: unclear from trials registry
Duration of treatment: unclear from trials registry
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed on days 5, 10, 15 and 20)
• Tumour size and response (not an outcome of this review)
Notes Emailed study investigators 29/06/2015 for publication details or full unpublished study data
Response:
"This was an M.Sc dissertation by a student from the institute of nursing and I was one of the
guides. I shall try and contact this student for complete details and then get back to you.
With regards,
Sushmita Ghoshal"
Status: still awaiting further details and therefore unable to include these valuable data in the re-
view
CTRI/2013/08/003906  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Suzhou, China
Number of centres: 1
Lu 2013 
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Study duration: unclear from abstract
Participants Inclusion criteria: unclear from abstract
Exclusion criteria: unclear from abstract
Cancer type: unclear from abstract
Cancer treatment: unclear from abstract (followed by HSCT)
Any other potentially important prognostic factors: unclear from abstract
Age at baseline (years): unclear from abstract
Gender: unclear from abstract
Number randomised: 37 (number per group unclear from abstract)
Number evaluated: unclear from abstract
Interventions Comparison: full cryotherapy versus partial cryotherapy
Gp A: oral cryotherapy from the beginning of chemotherapy infusion until the end of infusion
Gp B: oral cryotherapy starting half way through chemotherapy infusion until the end of infusion
All participants received basic oral care
Compliance: unclear from abstract
Duration of treatment: unclear from abstract
Outcomes • Oral mucositis: NCI-CTC 0 to 4 scale
• Duration of oral mucositis (not an outcome of this review)
Notes Unable to obtain email addresses for study investigators. Awaiting publication of full trial re-
port
Lu 2013  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: Columbus, Ohio, USA
Number of centres: 1
Study duration: April 2012 to March 2015
Participants Inclusion criteria: minimum 18 years of age; diagnosed with multiple myeloma and due to receive
autologous STC
Exclusion criteria: any other medical condition (including mental illness or substance abuse)
which may interfere with ability to give informed consent, co-operate, and participate in the study,
or which may interfere with the interpretation of the results
Cancer type: haematological (multiple myeloma)
Cancer treatment: high-dose melphalan followed by autologous SCT
Any other potentially important prognostic factors: unclear from trials registry
Age at baseline (years): unclear from trials registry
NCT01653106 
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Gender: unclear from trials registry
Number randomised: 146 (Gp A: 73; Gp B: 73)
Number evaluated: unclear from trials registry
Interventions Comparison: 2 hours of cryotherapy versus 6 hours of cryotherapy
Gp A: 1 ounce of shaved ice placed in mouth starting 15 min before receiving chemotherapy, and
replenished for 2 hours
Gp B: 1 ounce of shaved ice placed in mouth starting 15 min before receiving chemotherapy, and
replenished for 6 hours
Compliance: unclear from trials registry
Duration of treatment: 2 hours or 6 hours
Outcomes • Oral mucositis: NCI-CTC (4.0) 0 to 4 scale (incidence of severe mucositis i.e. grade 3 to 4, assessed
over 21 days)
• Melphalan pharmacokinetic modelling (not an outcome of this review)
Notes Emailed study investigators 24/09/2015 for publication details or full unpublished study data
NCT01653106  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: USA
Number of centres: unclear from abstract
Study duration: unclear from abstract
Participants Inclusion criteria: unclear from abstract
Exclusion criteria: unclear from abstract
Cancer type: unclear from abstract
Cancer treatment: high-dose melphalan (> 140 mg/m2) either alone or as part of the BEAM regi-
men, prior to autologous HSCT
Any other potentially important prognostic factors: unclear from abstract
Age at baseline (years): unclear from abstract
Gender: unclear from abstract
Number randomised: 40 (number per group unclear from abstract)
Number evaluated: unclear from abstract
Interventions Comparison: cryotherapy versus no treatment
Gp A: oral cryotherapy 5 min before the start of chemotherapy infusion, continuing until 30 min af-
ter the completion of infusion
Gp B: chemotherapy only
Compliance: unclear from abstract
Robenolt 2010 
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Duration of treatment: unclear from abstract
Outcomes • Oral mucositis: WHO 0 to 4 scale (assessed over 14 days)
• Oral pain: scale not reported (assessed over 14 days)
• Patient functioning: swallowing, eating, and talking (not outcomes of this review)
Notes Emailed study investigators 29/09/2015 for publication details or full unpublished study data
Robenolt 2010  (Continued)
 
 
Methods Trial design: parallel (2 arms)
Location: unclear from abstract
Number of centres: unclear from abstract
Study duration: unclear from abstract
Participants Inclusion criteria: minimum 18 years of age
Exclusion criteria: unclear from abstract
Cancer type: breast
Cancer treatment: super intensive chemotherapy (various types)
Any other potentially important prognostic factors: unclear from abstract
Age at baseline (years): unclear from abstract
Gender: females
Number randomised: 150 (number per group unclear from abstract)
Number evaluated: unclear from abstract
Interventions Comparison: cryotherapy versus control (unclear from abstract)
Gp A: details of regimen not described in abstract
Gp B: details of regimen not described in abstract
Compliance: unclear from abstract
Duration of treatment (intended): unclear from abstract
Outcomes • Duration of opioid use (fentanyl)
• Oral pain (assessed verbally daily)
Notes Emailed study investigators 29/09/2015 for publication details or full unpublished study data
Xourafas 2009 
autologous = patients' own cells; HSCT = haematopoietic stem cell transplantation; NCI-CTC = National Cancer Institute common toxicity
criteria; SCT = stem cell transplantation; WHO = World Health Organization
 
Characteristics of ongoing studies [ordered by study ID]
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Trial name or title A randomized controlled trial of cryotherapy for prevention and reduction of severity of oral mu-
cositis in children undergoing hematopoietic stem cell transplantation
Methods Trial design: parallel (2 arms)
Location: unclear from trials registry
Number of centres: unclear from trials registry
Study duration: October 2012 to estimated September 2015
Participants Inclusion criteria: aged between 4 and 18 years; due to receive chemotherapy as conditioning
treatment prior to HSCT in Sweden; sufficient knowledge of Swedish to understand the protocols
Exclusion criteria: not reported
Cancer type: haematological (multiple myeloma)
Cancer treatment: chemotherapy prior to HSCT
Any other potentially important prognostic factors: unclear from trials registry
Age at baseline (years): 4 to 18
Gender: unclear from trials registry
Number randomised: 50 (estimated enrolment - not reported by group)
Number evaluated: unclear from trials registry
Interventions Comparison: cryotherapy versus standard oral care
Gp A: ice chips/ice cream/ice water used during chemotherapy infusion, replenished continuously
(children receiving a 24-hour infusion instructed to use cryotherapy for 1 hour, 4 times per day)
Gp B: standard oral care
Compliance: unclear from trials registry
Duration of treatment: unclear from trials registry
Outcomes • Oral mucositis: 1) WHO 0 to 4 scale (assessed daily until HSCT, for expected average of 20 days);
2) ChiMES 0 to 23 scale (assessed daily by parent and child until HSCT, for expected average of
20 days)
• Oral pain (assessed daily by nurse until HSCT, for expected average of 20 days)
• Quality of life: emotional and psychological status using Beck youth inventories for depression
and anxiety (assessed daily until HSCT, for expected average of 20 days)
• Duration and dose of opioid use (during hospitalisation in connection with HSCT, for expected
average of 25 days)
• Normalcy of diet: duration of TPN (during hospitalisation in connection with HSCT, for expected
average of 25 days)
• Duration of hospital stay (in connection with HSCT)
• Pain (general: not an outcome of this review)
• Weight loss (not an outcome of this review)
• Duration of antibiotic treatment (not an outcome of this review)
• Duration of febrile neutropenia (not an outcome of this review)
• C-reactive protein level (not an outcome of this review)
• S-Albumin (not an outcome of this review)
Starting date October 2012
NCT01789658 
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Contact information Gustaf Ljungman (gustaf.ljungman@kbh.uu.se); Tove Kamsvåg Magnusson (tove.kamsvag_mag-
nusson@gmail.com)
Notes  
NCT01789658  (Continued)
 
 
Trial name or title Randomized controlled, open-label study on the use of cryotherapy in the prevention of
chemotherapy-induced mucositis in stem cell transplant patients
Methods Trial design: parallel (2 arms)
Location: Florida, USA
Number of centres: unclear from trials registry
Study duration: March 2015 to estimated March 2019
Participants Inclusion criteria: minimum 18 years of age; due to receive etoposide chemotherapy (minimum
dose of 30 mg/kg) as conditioning treatment prior to autologous SCT
Exclusion criteria: prior radiation to head and neck; known oropharynx involvement in malignan-
cy; history of non-compliance or lack capacity to give informed consent
Cancer type: unclear from trials registry
Cancer treatment: etoposide (minimum dose of 30 mg/kg) prior to autologous SCT
Any other potentially important prognostic factors: unclear from trials registry
Age at baseline (years): unclear from trials registry
Gender: unclear from trials registry
Number randomised: 48 (estimated enrolment - not reported by group)
Number evaluated: unclear from trials registry
Interventions Comparison: cryotherapy versus no treatment
Gp A: ice chips/other very cold or frozen food used starting 15 min before starting etoposide infu-
sion for a 30-min period, then 3 saline rinses over 15-min period. This alternating cycle is repeated
until 30 min after completion of etoposide infusion (total 150 min)
Gp B: at start of etoposide infusion 3 saline rinses over 15-min period followed by 30-rest period
(no treatment). This alternating cycle is repeated until 30 min after completion of etoposide infu-
sion (total 150 min)
All participants will receive standard oral care (saline rinses)
Compliance: unclear from trials registry
Duration of treatment: 150 min
Outcomes • Oral mucositis: scale not reported (assessed starting on day +1 post-transplant until discharged
from hospital, for expected average of 21 to 28 days)
• Time to onset of oral mucositis (not an outcome of this review)
• Duration of oral mucositis (not an outcome of this review)
NCT02326675 
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• Compliance: number of participants that tolerate cryotherapy during each infusion (not an out-
come of this review but we will record the information in the 'Characteristics of included studies'
tables)
Starting date March 2015
Contact information Christina Cline (clcline@ufl.edu); Leslie Pettiford (lpettiford@ufl.edu)
Notes  
NCT02326675  (Continued)
autologous = patients' own cells; ChiMES = Children's International Mucositis Evaluation Scale; HSCT = haematopoietic stem cell
transplantation; SCT = stem cell transplantation; TPN = total parenteral nutrition; WHO = World Health Organization
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Cryotherapy versus control
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Oral mucositis (any) 11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Fluorouracil (5FU) treatment 5 444 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.52, 0.72]
1.2 High-dose melphalan treatment
prior to stem cell transplantation
5 270 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.35, 1.01]
1.3 Methotrexate treatment post-stem
cell transplantation to prevent GVHD
1 122 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.90, 1.07]
2 Oral mucositis (moderate + severe) 11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Fluorouracil (5FU) treatment 5 444 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.41, 0.65]
2.2 High-dose melphalan treatment
prior to stem cell transplantation
5 270 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.17, 1.09]
2.3 Methotrexate treatment post-stem
cell transplantation to prevent GVHD
1 122 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.85, 1.20]
3 Oral mucositis (severe) 11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Fluorouracil (5FU) treatment 5 444 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.27, 0.61]
3.2 High-dose melphalan treatment
prior to stem cell transplantation
5 270 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.20, 0.72]
3.3 Methotrexate treatment post-stem
cell transplantation to prevent GVHD
1 122 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.61, 1.25]
4 Interruptions to cancer treatment 1 80 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.20, 0.95]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5 Interruptions to cancer treatment
(days of interruption)
1 80 Mean Difference (IV, Random, 95% CI) -8.0 [-9.26, -6.74]
6 Oral pain (0 to 10 scale) 2 85 Mean Difference (IV, Random, 95% CI) -1.50 [-2.11, -0.89]
7 Normalcy of diet (days of total par-
enteral nutrition)
1 78 Mean Difference (IV, Random, 95% CI) -2.18 [-4.33, -0.03]
8 Duration of hospitalisation (days) 2 123 Mean Difference (IV, Random, 95% CI) -1.39 [-2.97, 0.19]
9 Duration of opioid use (days) 1 78 Mean Difference (IV, Random, 95% CI) -2.28 [-5.33, 0.77]
 
 
Analysis 1.1.   Comparison 1 Cryotherapy versus control, Outcome 1 Oral mucositis (any).
Study or subgroup Cryotherapy Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Fluorouracil (5FU) treatment  
Mahood 1991 22/50 35/43 22.61% 0.54[0.38,0.76]
Cascinu 1994 14/44 20/40 9.44% 0.64[0.37,1.08]
Sorensen 2008 34/63 49/64 37.98% 0.7[0.54,0.92]
Katranci 2012 12/30 23/30 11.57% 0.52[0.32,0.84]
Heydari 2012 18/40 31/40 18.4% 0.58[0.4,0.85]
Subtotal (95% CI) 227 217 100% 0.61[0.52,0.72]
Total events: 100 (Cryotherapy), 158 (Control)  
Heterogeneity: Tau2=0; Chi2=2.12, df=4(P=0.71); I2=0%  
Test for overall effect: Z=5.87(P<0.0001)  
   
1.1.2 High-dose melphalan treatment prior to stem cell transplanta-
tion
 
Lilleby 2006 13/21 19/19 22.11% 0.63[0.45,0.88]
Svanberg 2007 35/39 36/39 23.88% 0.97[0.85,1.12]
Salvador 2012 6/23 15/22 16.47% 0.38[0.18,0.81]
Toro 2013 4/40 25/38 13.61% 0.15[0.06,0.4]
Askarifar 2015 16/16 13/13 23.93% 1[0.88,1.14]
Subtotal (95% CI) 139 131 100% 0.59[0.35,1.01]
Total events: 74 (Cryotherapy), 108 (Control)  
Heterogeneity: Tau2=0.3; Chi2=87.07, df=4(P<0.0001); I2=95.41%  
Test for overall effect: Z=1.93(P=0.05)  
   
1.1.3 Methotrexate treatment post-stem cell transplantation to pre-
vent GVHD
 
Gori 2007 58/62 57/60 100% 0.98[0.9,1.07]
Subtotal (95% CI) 62 60 100% 0.98[0.9,1.07]
Total events: 58 (Cryotherapy), 57 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.73)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours control
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Analysis 1.2.   Comparison 1 Cryotherapy versus control, Outcome 2 Oral mucositis (moderate + severe).
Study or subgroup Cryotherapy Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Fluorouracil (5FU) treatment  
Mahood 1991 13/50 24/43 19.74% 0.47[0.27,0.8]
Cascinu 1994 8/44 14/40 10% 0.52[0.24,1.11]
Sorensen 2008 16/63 31/64 23.51% 0.52[0.32,0.86]
Heydari 2012 18/40 31/40 39.32% 0.58[0.4,0.85]
Katranci 2012 5/30 15/30 7.43% 0.33[0.14,0.8]
Subtotal (95% CI) 227 217 100% 0.52[0.41,0.65]
Total events: 60 (Cryotherapy), 115 (Control)  
Heterogeneity: Tau2=0; Chi2=1.52, df=4(P=0.82); I2=0%  
Test for overall effect: Z=5.44(P<0.0001)  
   
1.2.2 High-dose melphalan treatment prior to stem cell transplanta-
tion
 
Lilleby 2006 5/21 15/19 20.26% 0.3[0.14,0.67]
Svanberg 2007 34/39 36/39 23.74% 0.94[0.81,1.1]
Salvador 2012 2/23 6/22 14.73% 0.32[0.07,1.41]
Toro 2013 4/40 21/38 18.88% 0.18[0.07,0.48]
Askarifar 2015 9/16 11/13 22.38% 0.66[0.41,1.09]
Subtotal (95% CI) 139 131 100% 0.43[0.17,1.09]
Total events: 54 (Cryotherapy), 89 (Control)  
Heterogeneity: Tau2=0.93; Chi2=50.48, df=4(P<0.0001); I2=92.08%  
Test for overall effect: Z=1.78(P=0.07)  
   
1.2.3 Methotrexate treatment post-stem cell transplantation to pre-
vent GVHD
 
Gori 2007 50/62 48/60 100% 1.01[0.85,1.2]
Subtotal (95% CI) 62 60 100% 1.01[0.85,1.2]
Total events: 50 (Cryotherapy), 48 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.09(P=0.93)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Cryotherapy versus control, Outcome 3 Oral mucositis (severe).
Study or subgroup Cryotherapy Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Fluorouracil (5FU) treatment  
Mahood 1991 7/50 14/43 24.81% 0.43[0.19,0.97]
Cascinu 1994 4/44 10/40 14.04% 0.36[0.12,1.07]
Sorensen 2008 7/63 21/64 26.69% 0.34[0.15,0.74]
Katranci 2012 1/30 4/30 3.59% 0.25[0.03,2.11]
Heydari 2012 8/40 16/40 30.86% 0.5[0.24,1.03]
Subtotal (95% CI) 227 217 100% 0.4[0.27,0.61]
Total events: 27 (Cryotherapy), 65 (Control)  
Heterogeneity: Tau2=0; Chi2=0.79, df=4(P=0.94); I2=0%  
Test for overall effect: Z=4.39(P<0.0001)  
   
1.3.2 High-dose melphalan treatment prior to stem cell transplanta-
tion
 
Favours cryotherapy 100.1 50.2 20.5 1 Favours control
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Study or subgroup Cryotherapy Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Lilleby 2006 3/21 14/19 20.92% 0.19[0.07,0.57]
Svanberg 2007 13/39 21/39 37.77% 0.62[0.36,1.05]
Salvador 2012 2/23 4/22 12.4% 0.48[0.1,2.35]
Toro 2013 0/40 9/38 4.78% 0.05[0,0.83]
Askarifar 2015 4/16 8/13 24.13% 0.41[0.16,1.05]
Subtotal (95% CI) 139 131 100% 0.38[0.2,0.72]
Total events: 22 (Cryotherapy), 56 (Control)  
Heterogeneity: Tau2=0.21; Chi2=6.95, df=4(P=0.14); I2=42.44%  
Test for overall effect: Z=2.96(P=0)  
   
1.3.3 Methotrexate treatment post-stem cell transplantation to pre-
vent GVHD
 
Gori 2007 29/62 32/60 100% 0.88[0.61,1.25]
Subtotal (95% CI) 62 60 100% 0.88[0.61,1.25]
Total events: 29 (Cryotherapy), 32 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.72(P=0.47)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Cryotherapy versus control, Outcome 4 Interruptions to cancer treatment.
Study or subgroup Cryotherapy Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heydari 2012 7/40 16/40 100% 0.44[0.2,0.95]
   
Total (95% CI) 40 40 100% 0.44[0.2,0.95]
Total events: 7 (Cryotherapy), 16 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.1(P=0.04)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.5.   Comparison 1 Cryotherapy versus control, Outcome
5 Interruptions to cancer treatment (days of interruption).
Study or subgroup Cryotherapy Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heydari 2012 40 6 (1.7) 40 14 (3.7) 100% -8[-9.26,-6.74]
   
Total *** 40   40   100% -8[-9.26,-6.74]
Heterogeneity: Not applicable  
Test for overall effect: Z=12.46(P<0.0001)  
Favours cryotherapy 105-10 -5 0 Favours control
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Analysis 1.6.   Comparison 1 Cryotherapy versus control, Outcome 6 Oral pain (0 to 10 scale).
Study or subgroup Cryotherapy Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Lilleby 2006 21 0.6 (2.1) 19 2.7 (2.1) 21.29% -2.1[-3.4,-0.8]
Salvador 2012 23 0.3 (1.1) 22 1.6 (1.1) 78.71% -1.34[-1.99,-0.69]
   
Total *** 44   41   100% -1.5[-2.11,-0.89]
Heterogeneity: Tau2=0.01; Chi2=1.05, df=1(P=0.31); I2=4.33%  
Test for overall effect: Z=4.83(P<0.0001)  
Favours cryotherapy 105-10 -5 0 Favours control
 
 
Analysis 1.7.   Comparison 1 Cryotherapy versus control,
Outcome 7 Normalcy of diet (days of total parenteral nutrition).
Study or subgroup Cryotherapy Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Svanberg 2007 39 5 (4.6) 39 7.2 (5.1) 100% -2.18[-4.33,-0.03]
   
Total *** 39   39   100% -2.18[-4.33,-0.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.99(P=0.05)  
Favours cryotherapy 105-10 -5 0 Favours control
 
 
Analysis 1.8.   Comparison 1 Cryotherapy versus control, Outcome 8 Duration of hospitalisation (days).
Study or subgroup Cryotherapy Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Svanberg 2007 39 24.2 (7.9) 39 28.4 (18.4) 6.33% -4.21[-10.51,2.09]
Salvador 2012 23 14.1 (2.8) 22 15.3 (2.8) 93.67% -1.2[-2.84,0.44]
   
Total *** 62   61   100% -1.39[-2.97,0.19]
Heterogeneity: Tau2=0; Chi2=0.82, df=1(P=0.36); I2=0%  
Test for overall effect: Z=1.72(P=0.09)  
Favours cryotherapy 105-10 -5 0 Favours control
 
 
Analysis 1.9.   Comparison 1 Cryotherapy versus control, Outcome 9 Duration of opioid use (days).
Study or subgroup Cryotherapy Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Svanberg 2007 39 3.4 (5.3) 39 5.7 (8.2) 100% -2.28[-5.33,0.77]
   
Total *** 39   39   100% -2.28[-5.33,0.77]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.46(P=0.14)  
Favours cryotherapy 105-10 -5 0 Favours control
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Comparison 2.   Di=erent oral cryotherapy regimens
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Oral mucositis (any) 1 178 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.62, 1.29]
2 Oral mucositis (moderate + severe) 1 178 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.36, 1.30]
3 Oral mucositis (severe) 1 178 Risk Ratio (M-H, Random, 95% CI) 0.6 [0.23, 1.58]
 
 
Analysis 2.1.   Comparison 2 Di=erent oral cryotherapy regimens, Outcome 1 Oral mucositis (any).
Study or subgroup 30 minutes 60 minutes Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Rocke 1993 33/89 37/89 100% 0.89[0.62,1.29]
   
Total (95% CI) 89 89 100% 0.89[0.62,1.29]
Total events: 33 (30 minutes), 37 (60 minutes)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Favours 30 minutes 100.1 50.2 20.5 1 Favours 60 minutes
 
 
Analysis 2.2.   Comparison 2 Di=erent oral cryotherapy regimens, Outcome 2 Oral mucositis (moderate + severe).
Study or subgroup 30 minutes 60 minutes Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Rocke 1993 13/89 19/89 100% 0.68[0.36,1.3]
   
Total (95% CI) 89 89 100% 0.68[0.36,1.3]
Total events: 13 (30 minutes), 19 (60 minutes)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.16(P=0.25)  
Favours 30 minutes 100.1 50.2 20.5 1 Favours 60 minutes
 
 
Analysis 2.3.   Comparison 2 Di=erent oral cryotherapy regimens, Outcome 3 Oral mucositis (severe).
Study or subgroup 30 minutes 60 minutes Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Rocke 1993 6/89 10/89 100% 0.6[0.23,1.58]
   
Total (95% CI) 89 89 100% 0.6[0.23,1.58]
Total events: 6 (30 minutes), 10 (60 minutes)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
Favours 30 minutes 100.1 50.2 20.5 1 Favours 60 minutes
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
69
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Comparison 3.   Cryotherapy versus chlorhexidine
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Oral mucositis (any) 1 133 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.71, 1.32]
2 Oral mucositis (moderate + severe) 1 133 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.51, 1.56]
3 Oral mucositis (severe) 1 133 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.34, 2.18]
 
 
Analysis 3.1.   Comparison 3 Cryotherapy versus chlorhexidine, Outcome 1 Oral mucositis (any).
Study or subgroup Cryotherapy Chlorhexidine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sorensen 2008 34/63 39/70 100% 0.97[0.71,1.32]
   
Total (95% CI) 63 70 100% 0.97[0.71,1.32]
Total events: 34 (Cryotherapy), 39 (Chlorhexidine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.2(P=0.84)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours chlorhexidine
 
 
Analysis 3.2.   Comparison 3 Cryotherapy versus chlorhexidine, Outcome 2 Oral mucositis (moderate + severe).
Study or subgroup Cryotherapy Chlorhexidine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sorensen 2008 16/63 20/70 100% 0.89[0.51,1.56]
   
Total (95% CI) 63 70 100% 0.89[0.51,1.56]
Total events: 16 (Cryotherapy), 20 (Chlorhexidine)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.41(P=0.68)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours chlorhexidine
 
 
Analysis 3.3.   Comparison 3 Cryotherapy versus chlorhexidine, Outcome 3 Oral mucositis (severe).
Study or subgroup Cryotherapy Chlorhexidine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sorensen 2008 7/63 9/70 100% 0.86[0.34,2.18]
   
Total (95% CI) 63 70 100% 0.86[0.34,2.18]
Total events: 7 (Cryotherapy), 9 (Chlorhexidine)  
Heterogeneity: Not applicable  
Favours cryotherapy 100.1 50.2 20.5 1 Favours chlorhexidine
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Study or subgroup Cryotherapy Chlorhexidine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.31(P=0.76)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours chlorhexidine
 
 
Comparison 4.   Cryotherapy versus leucovorin
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Oral mucositis (any) 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Low-dose leucovorin (3 mg
daily)
1 118 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.50, 0.90]
1.2 High-dose leucovorin (200 mg
daily)
1 81 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.47, 0.90]
2 Oral mucositis (moderate + se-
vere)
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Low-dose leucovorin (3 mg
daily)
1 118 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.01, 3.42]
2.2 High-dose leucovorin (200 mg
daily)
1 81 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Oral mucositis (severe) 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Low-dose leucovorin (3 mg
daily)
1 118 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 High-dose leucovorin (200 mg
daily)
1 81 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 4.1.   Comparison 4 Cryotherapy versus leucovorin, Outcome 1 Oral mucositis (any).
Study or subgroup Cryotherapy Leucovorin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Low-dose leucovorin (3 mg daily)  
Zhang 2011 27/52 51/66 100% 0.67[0.5,0.9]
Subtotal (95% CI) 52 66 100% 0.67[0.5,0.9]
Total events: 27 (Cryotherapy), 51 (Leucovorin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.66(P=0.01)  
   
4.1.2 High-dose leucovorin (200 mg daily)  
Zhang 2011 27/52 23/29 100% 0.65[0.47,0.9]
Subtotal (95% CI) 52 29 100% 0.65[0.47,0.9]
Favours cryotherapy 100.1 50.2 20.5 1 Favours leucovorin
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Study or subgroup Cryotherapy Leucovorin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 27 (Cryotherapy), 23 (Leucovorin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.59(P=0.01)  
Favours cryotherapy 100.1 50.2 20.5 1 Favours leucovorin
 
 
Analysis 4.2.   Comparison 4 Cryotherapy versus leucovorin, Outcome 2 Oral mucositis (moderate + severe).
Study or subgroup Cryotherapy Leucovorin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.2.1 Low-dose leucovorin (3 mg daily)  
Zhang 2011 0/52 3/66 100% 0.18[0.01,3.42]
Subtotal (95% CI) 52 66 100% 0.18[0.01,3.42]
Total events: 0 (Cryotherapy), 3 (Leucovorin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.25)  
   
4.2.2 High-dose leucovorin (200 mg daily)  
Zhang 2011 0/52 0/29   Not estimable
Subtotal (95% CI) 52 29 Not estimable
Total events: 0 (Cryotherapy), 0 (Leucovorin)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours cryotherapy 100.1 50.2 20.5 1 Favours leucovorin
 
 
Analysis 4.3.   Comparison 4 Cryotherapy versus leucovorin, Outcome 3 Oral mucositis (severe).
Study or subgroup Cryotherapy Leucovorin Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.3.1 Low-dose leucovorin (3 mg daily)  
Zhang 2011 0/52 0/66   Not estimable
Subtotal (95% CI) 52 66 Not estimable
Total events: 0 (Cryotherapy), 0 (Leucovorin)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.3.2 High-dose leucovorin (200 mg daily)  
Zhang 2011 0/52 0/29   Not estimable
Subtotal (95% CI) 52 29 Not estimable
Total events: 0 (Cryotherapy), 0 (Leucovorin)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours cryotherapy 100.1 50.2 20.5 1 Favours leucovorin
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A D D I T I O N A L   T A B L E S
 
Outcome Study Description of data Cryother-
apy
Control Result
Oral mu-
cositis
Kakoei
2013
WHO 0 to 4 scale; physi-
cian-judged rating used; day 14
data used due to highest control
group mean (should be noted
that on days 1 and 7 the cryother-
apy group mean is higher but
with no statistically significant
difference)
n = 20
mean 0.95
(SD 0.58)
n = 20
mean 1.2
(SD 0.89)
MD -0.25 (95% CI -0.72 to 0.22); P = 0.29
(there is no evidence of a difference in
mucositis severity)
Oral pain Heydari
2012
1 to 5 scale: 1 = never, 2 = 1 day of
week, 3 = 2 to 3 days of week, 4 =
most of week, 5 = 7 days of week
n = 40
mean 1.71
(SD 0.74)
n = 40
mean 3.64
(SD 1.20)
MD -1.93 (95% CI -2.37 to -1.49); P <
0.00001 (cryotherapy statistically signifi-
cantly reduced the duration of pain expe-
rience)
Normalcy
of diet
Lilleby
2006
Days of TPN (we use the P value
quoted in the study report)
n = 21
median 2
(range 0
to 15)
n = 19
median
5.5 (range
0 to 21)
P = 0.04 (cryotherapy statistically signif-
icantly reduced the number of days of
TPN)
Number
of days in
hospital
Lilleby
2006
Days of hospitalisation (we use
the P value quoted in the study
report)
n = 21
median 9
(range 0
to 22)
n = 19
median 14
(range 0
to 30)
P = 0.11 (there is no evidence of a differ-
ence in the number of days of hospitalisa-
tion)
Number
of days
of treat-
ment
with opi-
oid anal-
gesics
Lilleby
2006
Days of IV narcotics (we use the P
value quoted in the study report)
n = 21
median 0
(range 0
to 10)
n = 19
median
5.5 (range
0 to 13)
P = 0.0003 (cryotherapy statistically sig-
nificantly reduced the number of days of
IV narcotics)
Table 1.   Study data not included in analyses 
CI = confidence interval; IV = intravenous; MD = mean diEerence; n = number of participants analysed; N/A = not applicable; SD = standard
deviation; TPN = total parenteral nutrition
 
 
A P P E N D I C E S
Appendix 1. Cochrane Oral Health Group Trials Register search strategy
1 ((neoplasm* or cancer* or tumor* or tumour*):ti,ab) AND (INREGISTER)
2 ((leukaemi* or leukemi*):ti,ab) AND (INREGISTER)
3 ((malignan* or neutropeni* or carcino* or adenocarcinoma* or lymphoma*):ti,ab) AND (INREGISTER)
4 ((radioth* or radiat* or irradiat*):ti,ab) AND (INREGISTER)
5 (("bone marrow transplant*"):ti,ab) AND (INREGISTER)
6 ((chemo*):ti,ab) AND (INREGISTER)
7 (#1 or #2 or #3 or #4 or #5 or #6) AND (INREGISTER)
8 ((stomatitis or mucositis):ti,ab) AND (INREGISTER)
9 ((oral and mucos*):ti,ab) AND (INREGISTER)
10 ((mycosis or mycotic):ti,ab) AND (INREGISTER)
11 (mIAS:ti,ab) AND (INREGISTER)
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12 (#8 or #9 or #10 or #11) AND (INREGISTER)
13 (cryotherap*:ti,ab) AND (INREGISTER)
14 ((ice or freez* or cold*):ti,ab) AND (INREGISTER)
15 (#13 or #14) AND (INREGISTER)
16 (#7 and #12 and #15) AND (INREGISTER)
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1 [mh neoplasms]
#2 [mh leukemia]
#3 [mh lymphoma]
#4 [mh radiotherapy]
#5 [mh "antineoplastic agents"]
#6 (neoplasm* or cancer* or tumor* or tumour*)
#7 (leukaemi* or leukemi*)
#8 (malignan* or neutropeni* or carcino* or adenocarcinoma* or lymphoma*)
#9 "bone marrow transplant*"
#10 chemo*
#11 {or #1-#10}
#12 [mh stomatitis]
#13 [mh ^"candidiasis, oral"]
#14 stomatitis
#15 mucositis
#16 (oral near/6 mycos*)
#17 (mycosis or mycotic)
#18 mIAS:ti,ab
#19 {or #12-#18}
#20 [mh cryotherapy]
#21 cryotherap*
#22 (cold* or ice or freez*)
#23 {or #20-#22}
#24 #11 and #19 and #23
Appendix 3. MEDLINE (Ovid) search strategy
1. exp NEOPLASMS/
2. exp LEUKEMIA/
3. exp LYMPHOMA/
4. exp RADIOTHERAPY/
5. exp Antineoplastic agents/
6. Bone Marrow Transplantation/
7. neoplasm$.mp.
8. cancer$.mp.
9. (leukaemi$ or leukemi$).mp.
10. (tumour$ or tumor$).mp.
11. malignan$.mp.
12. neutropeni$.mp.
13. carcino$.mp.
14. adenocarcinoma$.mp.
15. lymphoma$.mp.
16. (radioth$ or radiat$ or irradiat$).mp.
17. (bone adj marrow adj5 transplant$).mp.
18. chemo$.mp.
19. or/1-18
20. exp STOMATITIS/
21. Candidiasis, Oral/
22. stomatitis.mp.
23. mucositis.mp.
24. (oral adj6 mucos$).mp.
25. (mycosis or mycotic).mp.
26. mIAS.ti,ab.
27. or/20-26
28. Cryotherapy/
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29. cryotherap$.mp.
30. (cold or freez$ or ice).mp.
31. or/28-30
32. 19 and 27 and 31
Appendix 4. EMBASE (Ovid) search strategy
1. exp NEOPLASM/
2. exp LEUKEMIA/
3. exp LYMPHOMA/
4. exp RADIOTHERAPY/
5. exp Antineoplastic agent/
6. Bone Marrow Transplantation/
7. neoplasm$.mp.
8. cancer$.mp.
9. (leukaemi$ or leukemi$).mp.
10. (tumour$ or tumor$).mp.
11. malignan$.mp.
12. neutropeni$.mp.
13. carcino$.mp.
14. adenocarcinoma$.mp.
15. lymphoma$.mp.
16. (radioth$ or radiat$ or irradiat$).mp.
17. (bone adj marrow adj5 transplant$).mp.
18. chemo$.mp.
19. or/1-18
20. exp STOMATITIS/
21. Thrush/
22. stomatitis.mp.
23. mucositis.mp.
24. (oral adj6 mucos$).mp.
25. (mycosis or mycotic).mp.
26. mIAS.ti,ab.
27. or/20-26
28. Cryotherapy/
29. cryotherap$.mp.
30. (cold or freez$ or ice).mp.
31. or/28-30
32. 19 and 27 and 31
The above subject search was linked to the Cochrane Oral Health Group filter for identifying RCTs in EMBASE via Ovid:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
16. 14 NOT 15
Appendix 5. CANCERLIT via PubMed search strategy
#31 (#19 and #26 and #30)
#30 (#27 or #28 or #29)
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#29 ((cold* or freez* or ice))
#28 cryotherap*
#27 cryotherapy [mh:noexp]
#26 (#20 or #21 or #22 or #23 or #24 or #25)
#25 mIAS [tiab]
#24 (mycosis or mycotic)
#23 mucositis
#22 stomatitis
#21 oral candidiasis [mh:noexp]
#20 stomatitis [mh:exp]
#19 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18)
#18 chemo*
#17 "bone marrow transplant*
#16 (radioth* or radiat* or irradiat*)
#15 lymphoma*
#14 adenocarcinoma*
#13 carcino*
#12 neutropeni*
#11 malignan*
#10 (tumor* or tumour*)
#9 (leukaemi* or leukemi*)
#8 cancer*
#7 neoplasm*
#6 bone marrow transplantation [mh:noexp]
#5 antineoplastic agents [mh:exp]
#4 radiotherapy [mh:exp]
#3 lymphoma [mh:exp]
#2 leukemia [mh:exp]
#1 neoplasm [mh:exp]
Appendix 6. CINAHL via EBSCO search strategy
S32 S19 and S27 and S31
S31 S28 or S29 or S30
S30 (cold* or ice or freez*)
S29 cryotherap*
S28 (mh "cryotherapy")
S27 S20 or S21 or S22 or S23 or S24 or S25 or S26
S26 TI mIAS OR AB mIAS
S25 (mycosis or mycotic)
S24 (oral N6 mucos*)
S23 mucositis
S22 stomatitis
S21 (mh "candidiasis, oral")
S20 (mh "stomatitis+")
S19 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18
S18 chemo*
S17 "bone marrow transplant*"
S16 (radioth* or radiat* or irradiat*)
S15 lymphoma*
S14 adenocarcinoma*
S13 carcino*
S12 neutropeni*
S11 malignan*
S10 (tumor* or tumour*)
S9 (leukaem* or leukem*)
S8 cancer*
S7 neoplasm*
S6 (MH "Bone marrow transplantation")
S5 (MH "Antineoplastic Agents+")
S4 (mh "radiotherapy+")
S3 (mh "lymphoma+")
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S2 (mh "leukemia+")
S1 (mh "neoplasms+")
Appendix 7. US National Institutes of Health trials registry (ClinicalTrials.gov) and the WHO International Clinical
Trials Registry Platform search strategies
mucositis and cryotherapy
mucositis and ice
mucositis and cold
Appendix 8. Oral mucositis measurement scales
Oral mucositis assessment scale (OMAS)
 
Oral cavity ulceration Oral cavity erythema
Grade 0 no lesion Grade 0 none
Grade 1 lesion < 1 cm2 Grade 1 not severe
Grade 2 lesion 1 to 3 cm2 Grade 2 severe
Grade 3 lesion > 3 cm2    
 
 
Ulceration and erythema are measured at 9 diEerent sites and summated to give a total mucositis score
National Cancer Institute (NCI) common toxicity criteria (CTC) (as reported in Lilleby 2006)
 
Grade 0 no mucositis
Grade 1 painless ulcers, erythema or mild soreness without lesions
Grade 2 painful erythema, edema or ulcers but can swallow
Grade 3 painful erythema, edema or ulcers preventing swallowing or requiring hydration or total parenteral
nutrition (feeding into vein rather than into gastrointestinal (GI) tract)
Grade 4 severe ulceration requiring prophylactic intubation
 
 
World Health Organization (WHO) scale (as reported in Gori 2007)
 
Grade 0 no mucositis
Grade 1 soreness ± erythema
Grade 2 erythema, ulcers. Patient can swallow solid diet
Grade 3 ulcers, extensive erythema. Patient cannot swallow solid diet
Grade 4 mucositis to the extent that alimentation is not possible
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
• In the section 'Types of interventions', we have clarified that head-to-head studies assessing diEerent oral cryotherapy regimens were
also eligible. We have also clarified that studies looking at complex interventions (e.g. cryotherapy plus laser versus laser) will be
excluded as we cannot rule out any important interaction between the two (or more) interventions.
• In the section 'Types of studies', we stated in the protocol that cross-over studies were to be excluded. However, in order to avoid losing
valuable data, we treated such studies as parallel studies by only using first-period data.
• In the section 'Assessment of risk of bias in included studies', we stated in the protocol that we would not assess blinding of participants
and personnel (performance bias), as it was not possible to use such blinding in any of the studies. We decided to include this domain
of risk of bias in our assessments in order to give the reader a clearer picture of the problems with our confidence in the estimates of
eEect. This also aEects the section 'Sensitivity analysis', as we are not able to carry out sensitivity analyses based on risk of bias.
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Antineoplastic Agents  [administration & dosage]  [adverse eEects];  Cryotherapy  [*methods];  Fluorouracil  [administration & dosage]
 [adverse eEects];  Hematopoietic Stem Cell Transplantation;  Melphalan  [administration & dosage]  [adverse eEects];  Mouth Diseases
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Randomized Controlled Trials as Topic;  Stomatitis  [chemically induced]  [*prevention & control]
MeSH check words
Adult; Humans
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
79
